

# International Nonproprietary Names for Pharmaceutical Substances (INN)

---

## RECOMMENDED International Nonproprietary Names: List 71

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–109) and Recommended (1–70) International Nonproprietary Names can be found in *Cumulative List No. 15, 2013* (available in CD-ROM only).

## Dénominations communes internationales des Substances pharmaceutiques (DCI)

### Dénominations communes internationales RECOMMANDÉES: Liste 71

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.


On trouvera d'autres listes de Dénominations communes internationales proposées (1–109) et recommandées (1–70) dans la *Liste récapitulative No. 15, 2013* (disponible sur CD-ROM seulement).

## Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

### Denominaciones Comunes Internacionales RECOMENDADAS: Lista 71

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9); Resolución EB115.R4 (EB115/2005/REC/1) EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–109) y Recomendadas (1–70) se encuentran reunidas en *Cumulative List No. 15, 2013* (disponible sólo en CD-ROM).

| Latin, English, French, Spanish:<br>Recommended INN | Chemical name or description; Molecular formula; Graphic formula  |
|---|---|
| DCI Recommandée                                     | Nom chimique ou description; Formule brute; Formule développée  |
| DCI Recomendada                                     | Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada   |
| <b>abaloparatidum</b><br>abaloparatide              | synthetic human parathyroid hormone (37-70) analogue:<br>C <sup>2,29</sup> -methyl[22-L-glutamic acid(F>E),23-L-leucine(F>L),25-L-glutamic acid(H>E),26-L-lysine(H>K),28-L-leucine(I>L),30-L-lysine(E>K),31-L-leucine(I>L)]human parathyroid hormone-related protein-(1-34)-proteinamide  |
| abaloparatide                                       | analogue de l'hormone parathyroïdienne humaine (37-70)<br>synthétique:<br>C <sup>2,29</sup> -méthyl[22-L-acide glutamique(F>E),23-L-leucine(F>L),25-L-acide glutamique(H>E),26-L-lysine(H>K),28-L-leucine(I>L),30-L-lysine(E>K),31-L-leucine(I>L)]protéine apparentée à l'hormone parathyroïdienne humaine-(1-34)-protéinamide  |
| abaloparatida                                       | análogo sintético de la hormona paratiroidea humana (37-70):<br>C <sup>2,29</sup> -metil[22-L-ácido glutámico(F>E),23-L-leucina(F>L),25-L-ácido glutámico(H>E),26-L-lisina(H>K),28-L-leucina(I>L),30-L-lisina(E>K),31-L-leucina(I>L)]proteína relacionada con la hormona paratiroidea humana-(1-34)-proteínamida<br><br>C <sub>174</sub> H <sub>300</sub> N <sub>56</sub> O <sub>49</sub><br><br>Sequence / Séquence / Secuencia<br>AVSEHQLLHD KGKSIQDLRR RELLEKLLXK LHTA 34<br><br>Modified residues / Résidus modifiés / Restos modificados<br> |
| <b>abecomotidum</b><br>abecomotide                  | human insulin-like growth factor 2 mRNA-binding protein 3 (IMP-3, hKOC)-(508-513)-peptide (part of the KH4 domain):<br>L-lysyl-L-threonyl-L-valyl-L-asparaginyl-L-α-glutamyl-L-leucyl-L-glutaminyl-L-asparaginyl-L-leucine  |
| abécomotide   | protéine 3, se liant à l'ARN messenger, du facteur 2 de croissance humain analogue de l'insuline (IMP-3, hKOC)-(508-513)-peptide (partie du domaine KH4):<br>L-lysyl-L-thréonil-L-valil-L-asparaginyl-L-α-glutamyl-L-leucyl-L-glutaminil-L-asparaginil-L-leucine  |
| abecomotida   | proteína 3, que se une al ARN mensajero del factor 2 de crecimiento humano análogo de la insulina (IMP-3, hKOC)-(508-513)-péptido (parte del dominio KH4):<br>L-lisil-L-treonil-L-valil-L-asparaginil-L-α-glutamil-L-leucil-L-glutaminil-L-asparaginil-L-leucina<br><br>C <sub>45</sub> H <sub>79</sub> N <sub>13</sub> O <sub>16</sub><br><br>Sequence / Séquence / Secuencia<br>KTVNELQNL 9   |

**abrituzumabum #****abrituzumab**

immunoglobulin G2-kappa, anti-[*Homo sapiens* ITGAV (integrin alphaV, CD51)], humanized monoclonal antibody; gamma2 heavy chain (1-447) with IGHG1 hinge region [humanized VH (*Homo sapiens* IGHV1-46\*01 (77.30%) -(IGHD)-IGHJ6\*01) [8.8.11] (1-118) -*Homo sapiens* IGHG (IGHG2\*03 CH1 (119-216), IGHG1 hinge C5>S (221) (217-231), IGHG2\*03 CH2 F84.3>A (296), N84.4>Q (297) (232-340), CH3 (341-445), CHS (446-447)) (119-447)], (132-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-33\*01 (86.30%) -IGKJ2\*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC\*01 (108'-214')]; dimer (227-227":230-230")-bisdisulfide

**abrituzumab**

immunoglobuline G2-kappa, anti-[*Homo sapiens* ITGAV (intégrine alphaV, CD51)], anticorps monoclonal humanisé; chaîne lourde gamma2 (1-447) avec une région charnière IGHG1 [VH humanisé (*Homo sapiens* IGHV1-46\*01 (77.30%) -(IGHD)-IGHJ6\*01) [8.8.11] (1-118) -*Homo sapiens* IGHG (IGHG2\*03 CH1 (119-216), IGHG1 charnière C5>S (221) (217-231), IGHG2\*03 CH2 F84.3>A (296), N84.4>Q (297) (232-340), CH3 (341-445), CHS (446-447)) (119-447)], (132-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-33\*01 (86.30%) -IGKJ2\*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC\*01 (108'-214')]; dimère (227-227":230-230")-bisdisulfure

**abrituzumab**

immunoglobulina G2-kappa, anti-[ ITGAV (integrina alfaV, CD51) de *Homo sapiens*], anticuerpo monoclonal humanizado; cadena pesada gamma2 (1-447) con una región bisagra GHG1 [VH humanizada (*Homo sapiens* IGHV1-46\*01 (77.30%) -(IGHD)-IGHJ6\*01) [8.8.11] (1-118) -*Homo sapiens* IGHG (IGHG2\*03 CH1 (119-216), IGHG1 bisagra C5>S (221) (217-231), IGHG2\*03 CH2 F84.3>A (296), N84.4>Q (297) (232-340), CH3 (341-445), CHS (446-447)) (119-447)], (132-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizada (*Homo sapiens* IGKV1-33\*01 (86.30%) -IGKJ2\*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC\*01 (108'-214')]; dímero (227-227":230-230")-bisdisulfuro

**Heavy chain / Chaîne lourde / Cadena pesada**

```
QVQLQQSGGE LAKPGASVKV SCASGYTFS SFWMHWRQA PGQGLEWIGY 50
INFRSGYTEY NEIFRDKATM TTDSTSTAY MELSSLRSED TAVVYCASF 100
GRGAMDYWGQ GTTIVTVSSAS TKGPSVFPLA PCSRSTSEST AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSNFGTQTYT 200
CNVDHKPSNT KVDKTVEPKS SDKTHTCPPC PAPPVAGPSV FLFPFKPKDT 250
LMISRTPEVT CVVVDVSHED PEVQFNWYVD GVEVHNAKTK PREEQAQSTF 300
RVVSVLTIVVH QDWLNGKEYK CKVSNKGLPA PIEKTIKSTK GQPREPQVYT 350
LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTTPMPLDS 400
DGSFPLYSKL TVDKSRWQQG NVFSCSVME ALHNHYTQKS LSLSPGK 447
```

**Light chain / Chaîne légère / Cadena ligera**

```
DIQMTQSPSS LSASVGDRTV ITCRASQDIS NYLAWYQQKPK GKAPKLLIYY 50
TSKIHSGVPS RFSGSGSGTD YTFTISSLQP EDIATYYCQQ GNTFPYTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNIFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEK 214
```

**Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro**

```
Intra-H (C23-C104) 22-96 145-201 261-321 367-425
                  22"-96" 145"-201" 261"-321" 367"-425"
Intra-L (C23-C104) 23'-88" 134'-194"
                  23'''-88''' 134'''-194'''
Inter-H-L (CH1 10-CL 126) 132-214' 132"-214'"
Inter-H-H (h 11, h 14) 227-227" 230-230"
```

**N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación**

None (owing to amino acid change: H CH2 N84.4>Q (297)), aucun (du au changement d'acide aminé), ninguno (a causa del cambio de ácido amino)

**acalisibum**


acalisib

6-fluoro-3-phenyl-2-[(1*S*)-1-(7*H*-purin-6-ylamino)ethyl]quinazolin-4(3*H*)-one

acalisib

6-fluoro-3-phényl-2-[(1*S*)-1-(7*H*-purin-6-ylamino)éthyl]quinazolin-4(3*H*)-one

acalisib

6-fluoro-3-fenil-2-[(1*S*)-1-(7*H*-purin-6-ilamino)etil]quinazolin-4(3*H*)-onaC<sub>21</sub>H<sub>16</sub>FN<sub>7</sub>O**aftobetinum**

aftobetin

2-[2-(2-methoxyethoxy)ethoxy]ethyl (2*E*)-2-cyano-3-[6-(piperidin-1-yl)naphthalen-2-yl]prop-2-enoate


aftobétine

(2*E*)-2-cyano-3-[6-(pipéridin-1-yl)naftalén-2-yl]prop-2-énoate de 2-[2-(2-méthoxyéthoxy)éthoxy]éthyle

aftobetina

(2*E*)-2-ciano-3-[6-(piperidin-1-il)naftalen-2-il]prop-2-enoato de 2-[2-(2-metoxietoxi)etoxi]etiloC<sub>26</sub>H<sub>32</sub>N<sub>2</sub>O<sub>5</sub>

1208971-05-4

**alicdamotidum**

alicdamotide

human kinetochore protein Nuf2 (cell division cycle-associated protein 1)-(55-64)-peptide

alicdamotide

protéine cinétochore Nuf2 humaine (protéine 1 associée au cycle de la division cellulaire)-(55-64)-peptide

alicdamotida

proteína humana de cinetocoro Nuf2 (proteína 1 asociada al ciclo de división celular)-(55-64)-péptido

C<sub>54</sub>H<sub>80</sub>N<sub>14</sub>O<sub>13</sub>Sequence / Séquence / Secuencia  
VYGIRLEHF 9

**anetumabum ravtansinum #**  
anetumab ravtansine

immunoglobulin G1-lambda2, anti-[*Homo sapiens* MSLN (mesothelin, pre-pro-megakaryocyte-potentiating factor, megakaryocyte potentiating factor, MPF, CAK1)], *Homo sapiens* monoclonal antibody conjugated to maytansinoid DM4; gamma1 heavy chain (1-450) [*Homo sapiens* VH (IGHV5-51\*01 (94.90%) -(IGHD)-IGHJ4\*01) [8.8.13] (1-120) -IGHG1\*01 (CH1 (121-218), hinge (219-233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (223-216')-disulfide with lambda light chain (1'-217') [*Homo sapiens* V-LAMBDA (IGLV2-14\*01 (95.60%) -IGLJ2\*01) [9.3.11] (1'-111') -IGLC2\*01 A43>G (155) (112'-217')]; dimer (229-229":232-232")-bisdisulfide; conjugated, on an average of 3 lysyl, to maytansinoid DM4 [*N*<sup>2</sup>-deacetyl-*N*<sup>2</sup>-(4-mercapto-4-methyl-1-oxopentyl)-maytansine] via the reducible SPDB linker [N-succinimidyl 4-(2-pyridyldithio)butanoate]  
For the *ravtansine* part, please refer to the document "*INN for pharmaceutical substances: Names for radicals, groups and others*"

anétumab ravtansine

immunoglobuline G1-lambda2, anti-[*Homo sapiens* MSLN (mésothéline, facteur de potentialisation du pré-pro-mégacaryocyte, facteur de potentialisation des mégacaryocytes, MPF, CAK1)], *Homo sapiens* anticorps monoclonal conjugué au maytansinoïde DM4; chaîne lourde gamma1 (1-450) [*Homo sapiens* VH (IGHV5-51\*01 (94.90%) -(IGHD)-IGHJ4\*01) [8.8.13] (1-120) -IGHG1\*01 (CH1 (121-218), charnière (219-233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (223-216')-disulfure avec la chaîne légère lambda (1'-217') [*Homo sapiens* V-LAMBDA (IGLV2-14\*01 (95.60%) -IGLJ2\*01) [9.3.11] (1'-111') -IGLC2\*01 A43>G (155) (112'-217')]; dimère 229-229":232-232")-bisdisulfure; conjugué, sur 3 lysyl en moyenne, au maytansinoïde DM4 [*N*<sup>2</sup>-déacétyl-*N*<sup>2</sup>-(4-mercapto-4-méthyl-1-oxopentyl)-maytansine] via le linker SPDB réductible [4-(2-pyridyldithio)butanoate de N-succinimidyle]  
Pour la partie *ravtansine*, veuillez-vous référer au document "*INN for pharmaceutical substances: Names for radicals, groups and others*".

anetumab ravtansina

immunoglobulina G1-lambda2, anti-[MSLN de *Homo sapiens* (mesotelina, factor de potenciación del pre-pro-megacariocito, factor de potenciación de megacariocitos, MPF, CAK1)], anticuerpo monoclonal de *Homo sapiens* conjugado con el maitansinoide DM4; cadena pesada gamma1 (1-450) [*Homo sapiens* VH (IGHV5-51\*01 (94.90%) -(IGHD)-IGHJ4\*01) [8.8.13] (1-120) -IGHG1\*01 (CH1 (121-218), bisagra (219-233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (223-216')-disulfuro con la cadena ligera lambda (1'-217') [*Homo sapiens* V-LAMBDA (IGLV2-14\*01 (95.60%) -IGLJ2\*01) [9.3.11] (1'-111') -IGLC2\*01 A43>G (155) (112'-217')]; dimère 229-229":232-232")-bisdisulfuro; conjugado, en tres restos lisil por término medio, con el maitansinoide DM4 [*N*<sup>2</sup>-desacetil-*N*<sup>2</sup>-(4-mercapto-4-metil-1-oxopentil)-maitansina] mediante el conector SPDB reducible [4-(2-piridilditio)butanoato de N-succinimidilo]  
La información sobre la *ravtansina*, la encontrarán en el documento "*INN for pharmaceutical substances: Names for radicals, groups and others*".

Heavy chain / Chaîne lourde / Cadena pesada  
 QVELVQSGAE VKKPGESLKI SCKGSGYSFT SYWIGWVRQA PGKGLEWMI 50  
 IDPGDSRTRY SPSFQGVVTI SADKSIATY LQWSSLKASD TAMYVCARGQ 100  
 LYGGTYMDGW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAAAGCLVK 150  
 DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200  
 YICNVNHHKPS NTKVDKKVEP KSCDKHTCF PCPAPELLGG PSVFLFPPKP 250  
 KDTLMISRTF EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300  
 STYRVVSVLT VTHQDWLNGK EYCKKVSNA LPAPIEKTIS KAKGQPREPQ 350  
 VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTTPV 400  
 LDSDGSEFFLY SKLTVDKSRW QQGNVFCSCV MHEALHNHYT QKSLSLSPGK 450

Light chain / Chaîne légère / Cadena ligera  
 DIALTPASV SGSPGQSITI SCTGTSSDIG GYNSVSWYQQ HPGKAPKLM 50  
 YGVNNRPSGV SNRFSGSKSG NTASLTISGL QAEDADYYC SSYDIESATP 100  
 VFGGKTCLTV LGQPKAAPSV TLFPPSSEEL QANKATLVCL ISDFYPGAVT 150  
 VAWKGDSPV KAGVETTPS KQSNNKYAAS SYLSLTPEQW KSHRSYSCQV 200  
 THEGSTVEKT VAPTECS 217

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 147-203 264-324 370-428  
 22"-96" 147"-203" 264"-324" 370"-428"

Intra-L (C23-C104) 22"-90" 139"-198"  
 22"-90" 139"-198"

Inter-H-L (h 5-CL 126) 223-216' 223"-216"  
 Inter-H-H (h 11, h 14) 229-229" 232-232"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:  
 300, 300"

For the *ravtansine* part, please refer to the document "INN for pharmaceutical substances: Names for radicals, groups and others".

Pour la partie *ravtansine*, veuillez vous référer au document "INN for pharmaceutical substances: Names for radicals, groups and others".

Para la fracción *ravtansina*, se pueden dirigir al documento "INN for pharmaceutical substances: Names for radicals, groups and others".

## anifrolumabum # anifrolumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* IFNAR1 (interferon alpha, beta and omega receptor 1, interferon alpha/beta receptor 1)], *Homo sapiens* monoclonal antibody;  
 gamma1 heavy chain (1-447) [*Homo sapiens* VH (IGHV5-51\*01 (93.90%) -(IGHD)-IGHJ2\*01) [8.8.10] (1-117) -IGHG1\*01 (CH1 (118-215), hinge (216-230), CH2 L1.3>F (234), L1.2>E (235), P116>S (331) (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-215')-disulfide with kappa light chain (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20\*01 (94.70%) -IGKJ5\*01) [7.3.9] (1'-108') -IGKC\*01 (109'-215')]; dimer (226-226":229-229")-bisdisulfide

## anifrolumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* IFNAR1 (récepteur 1 de l'interféron alpha, bêta and oméga, récepteur de l'interféron alpha/bêta)], *Homo sapiens* anticorps monoclonal;  
 chaîne lourde gamma1 (1-447) [*Homo sapiens* VH (IGHV5-51\*01 (93.90%) -(IGHD)-IGHJ2\*01) [8.8.10] (1-117) -IGHG1\*01 (CH1 (118-215), charnière (216-230), CH2 L1.3>F (234), L1.2>E (235), P116>S (331) (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-215')-disulfure avec la chaîne légère kappa (1'-215') [*Homo sapiens* V- KAPPA (IGKV3-20\*01 (94.70%) -IGKJ5\*01) [7.3.9] (1'-108') -IGKC\*01 (109'-215')]; dimère (226-226":229-229")-bisdisulfure

## anifrolumab

immunoglobulina G1-kappa, anti-[IFNAR1 de *Homo sapiens* (receptor 1 de interferón alfa, beta and omega, receptor de interferón alfa/beta)], anticuerpo monoclonal de *Homo sapiens* ;  
 cadena pesada gamma1 (1-447) [*Homo sapiens* VH (IGHV5-51\*01 (93.90%) -(IGHD)-IGHJ2\*01) [8.8.10] (1-117) -IGHG1\*01 (CH1 (118-215), bisagra (216-230), CH2 L1.3>F (234), L1.2>E (235), P116>S (331) (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-215')-disulfuro con la cadena ligera kappa (1'-215') [*Homo sapiens* V- KAPPA (IGKV3-20\*01 (94.70%) -IGKJ5\*01) [7.3.9] (1'-108') -IGKC\*01 (109'-215')]; dímero (226-226":229-229")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

|            |            |             |            |            |     |
|------------|------------|-------------|------------|------------|-----|
| EVQLVQSGAE | VKKPGESLKI | SCKGSQYIFT  | NYWIAWVRQM | PGKGLESMGI | 50  |
| IYPGDSDIRY | SPSFQGGVTI | SADKSITITAY | LQWSSLKASD | TAMYICARHD | 100 |
| IEGFDYWGRG | TLVTVSSAST | KGPSVFPLAP  | SSKSTSGGTA | ALGCLVKDYF | 150 |
| PEPVTVSWNS | GALTSGVHTF | PAVLQSSGLY  | SLSSVVTGPS | SSLGTQTYIC | 200 |
| NVNHKPSNTK | VDKRVEPKSC | DKHTCPCPCP  | APEFEGGPSV | FLFPPKPKDT | 250 |
| LMISRTPEVT | CVVVDVSHED | PEVKFNWYVD  | GVEVHNAKTK | PREEQYNSTY | 300 |
| RVVSVLTVLH | QDWLNGKEYK | CKVSNKALPA  | SIEKTIKAK  | GQPREPQVYT | 350 |
| LPPSREEMTK | NQVSLTCLVK | GFYPDSIAVE  | WESNGQPENN | YKTTTPPVLD | 400 |
| DGSFFLYSKL | TVDKSRWQQG | NVFSQSVME   | ALHNHYTQKS | LSLSFGK    | 447 |

Light chain / Chaîne légère / Cadena ligera

|            |            |            |            |            |     |
|------------|------------|------------|------------|------------|-----|
| EIVLTQSPGT | LSLSPGERAT | LSCRASQSVS | SSFFAWYQQK | PGQAPRLLIY | 50  |
| GASSRATGIP | DRLSGSGSGT | DFTLTITRLE | PEDFAVYYCQ | QYDSSAITFG | 100 |
| QGTRLEIKRT | VAAPSVFIFP | PSDEQLKSGT | ASVVCLLNNF | YPREAKVQWK | 150 |
| VDNALQSGNS | QESVTEQDSK | DSTYSLSTL  | TLSKADYEKH | KVYACEVTHQ | 200 |
| GLSSPVTKSF | NRGEC      |            |            |            | 215 |

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 144-200 261-321 367-425  
22"-96" 144"-200" 261"-321" 367"-425"

Intra-L (C23-C104) 23'-89' 135'-195'  
23'''-89''' 135'''-195'''

Inter-H-L (h 5-CL 126) 220-215' 220"-215"

Inter-H-H (h 11, h 14) 226-226" 229-229"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:  
297, 297"

### artefenomelum

artefenomel

4-{2-[4-(*cis*-dispiro[adamantane-2,3'-[1,2,4]trioxolane-5',1"-cyclohexane]-4"-yl)phenoxy]ethyl}morpholine


artéfénomel

4-{2-[4-(*cis*-dispiro[adamantane-2,3'-[1,2,4]trioxolane-5',1"-cyclohexane]-4"-yl)phénoxy]éthyl}morpholine

artefenomel

4-{2-[4-(*cis*-diespiro[adamantano-2,3'-[1,2,4]trioxolano-5',1"-ciclohexano]-4"-il)fenoxi]etil}morfolina

C<sub>28</sub>H<sub>39</sub>NO<sub>5</sub>



### asapiprantum

asapiprant

2-[2-(oxazol-2-yl)-5-(4-{4-[(propan-2-yl)oxy]benzenesulfonyl}piperazin-1-yl)phenoxy]acetic acid


asapiprant

acide 2-[2-(oxazol-2-yl)-5-(4-{4-[(propan-2-yl)oxy]benzènesulfonyl}pipérazin-1-yl)phénoxy]acétique

asapiprant

ácido 2-[2-(oxazol-2-il)-5-(4-{4-[(propan-2-il)oxi]bencenosulfonyl}pipérazin-1-il)fenoxi]acético

C<sub>24</sub>H<sub>27</sub>N<sub>3</sub>O<sub>7</sub>S



**axelopranum**

axelopran


3-[(1*R*,3*r*,5*S*)-8-(2-{cyclohexylmethyl}[(2*S*)-2,3-dihydroxypropanoyl]amino)ethyl)-8-azabicyclo[3.2.1]octan-3-yl]benzamide

axélopran

3-[(1*R*,3*r*,5*S*)-8-(2-{(cyclohexylméthyl)}[(2*S*)-2,3-dihydroxypropanoyl]amino)éthyl)-8-azabicyclo[3.2.1]octan-3-yl]benzamide

axeloprán

3-[(1*R*,3*r*,5*S*)-8-(2-{ciclohexilmetil}[(2*S*)-2,3-dihidroxiopropanoil]amino)etil)-8-azabicyclo[3.2.1]octan-3-il]benzamida

C<sub>26</sub>H<sub>39</sub>N<sub>3</sub>O<sub>4</sub>**basimglurantum**

basimglurant


2-chloro-4-{2-[1-(4-fluorophenyl)-2,5-dimethyl-1*H*-imidazol-4-yl]ethynyl}pyridine

basimglurant

2-chloro-4-{2-[1-(4-fluorophényl)-2,5-diméthyl-1*H*-imidazol-4-yl]éthynyl}pyridine

basimglurant

2-cloro-4-{2-[1-(4-fluorofenil)-2,5-dimetil-1*H*-imidazol-4-il]etin-1-il}piridina

C<sub>18</sub>H<sub>13</sub>ClFN<sub>3</sub>**binimetinibum**

binimetinib

5-[(4-bromo-2-fluorophenyl)amino]-4-fluoro-*N*-(2-hydroxyethoxy)-1-methyl-1*H*-benzimidazole-6-carboxamide


binimétinib

5-[(4-bromo-2-fluorophényl)amino]-4-fluoro-*N*-(2-hydroxyéthoxy)-1-méthyl-1*H*-benzimidazole-6-carboxamide

binimetinib

5-[(4-bromo-2-fluorofenil)amino]-4-fluoro-*N*-(2-hidroxiétoxi)-1-metil-1*H*-benzoimidazol-6-carboxamida



**ceralifimodum**

ceralifimod



1-({6-[(2-methoxy-4-propylphenyl)methoxy]-1-methyl-3,4-dihydronaphthalen-2-yl)methyl}azetidine-3-carboxylic acid

céralifimod

acide 1-({6-[(2-méthoxy-4-propylphényl)méthoxy]-1-méthyl-3,4-dihydronaphtalén-2-yl)méthyl}azétidine-3-carboxylique

ceralifimod

ácido 1-({1-metil-6-[(2-metoxi-4-propilfenil)metoxi]-3,4-dihidronaftalen-2-il}metil)azetidina-3-carboxílico

**ceritinibum**

ceritinib


5-chloro-*N*<sup>2</sup>-{5-methyl-4-(piperidin-4-yl)-2-[(propan-2-yl)oxy]phenyl}-*N*<sup>4</sup>-[2-(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine

céritinib

5-chloro-*N*<sup>2</sup>-{5-méthyl-4-(pipéridin-4-yl)-2-[(propan-2-yl)oxy]phényl}-*N*<sup>4</sup>-[2-(propane-2-sulfonyl)phényl]pyrimidine-2,4-diamine

ceritinib

5-cloro-*N*<sup>2</sup>-{5-metil-4-(piperidin-4-il)-2-[(propan-2-il)oxi]fenil}-*N*<sup>4</sup>-[2-(propano-2-sulfonyl)fenil]pirimidina-2,4-diamina

**codrituzumabum #**

codrituzumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* GPC3 (glypican 3)], humanized monoclonal antibody; gamma1 heavy chain (1-445) [humanized VH (*Homo sapiens*IGHV1-46\*01 (82.70%) -(IGHD)-IGHJ5\*02) [8.8.8] (1-115) -*Homo sapiens*IGHG1\*01 (CH1 (116-213, hinge (214-228), CH2 (229-338), CH3 (339-443), CHS (444-445)) (116-445))], (218-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens*IGKV2-28\*01 (86.00%) -IGKJ2\*01) [11.3.9] (1'-112') -*Homo sapiens*IGKC\*01 (113'-219')]; dimer (224-224'':227'-227'')-bisdisulfide

## codrituzumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* GPC3 (glypican 3)], anticorps monoclonal humanisé;  
chaîne lourde gamma1 (1-445) [VH humanisé (*Homo sapiens* (*Homo sapiens*IGHV1-46\*01 (82.70%) -(IGHD)-IGHJ5\*02) [8.8.8] (1-115) -*Homo sapiens*IGHG1\*01 (CH1 (116-213, charnière (214-228), CH2 (229-338), CH3 (339-443), CHS (444-445)) (116-445)], (218-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens*IGKV2-28\*01 (86.00%) -IGKJ2\*01) [11.3.9] (1'-112') -*Homo sapiens*IGKC\*01 (113'-219')]; dimère (224-224'':227-227'')-bisdisulfure

## codrituzumab

immunoglobulina G1-kappa, anti-[GPC3 (glipicano 3) de *Homo sapiens*], anticuerpo monoclonal humanizado;  
cadena pesada gamma1 (1-445) [VH humanizado (*Homo sapiens* (*Homo sapiens*IGHV1-46\*01 (82.70%) -(IGHD)-IGHJ5\*02) [8.8.8] (1-115) -*Homo sapiens*IGHG1\*01 (CH1 (116-213, bisagra (214-228), CH2 (229-338), CH3 (339-443), CHS (444-445)) (116-445)], (218-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizado (*Homo sapiens*IGKV2-28\*01 (86.00%) -IGKJ2\*01) [11.3.9] (1'-112') -*Homo sapiens*IGKC\*01 (113'-219')]; dímero (224-224'':227-227'')-bisdisulfuro

## Heavy chain / Chaîne lourde / Cadena pesada

|            |             |            |            |            |     |
|------------|-------------|------------|------------|------------|-----|
| QVQLVQSGAE | VKKPGASVKV  | SCKASGYTFT | DYEMHWVRQA | PGQGLEWMGA | 50  |
| LDPKTDGTAY | SQKFKGRVTL  | TADKSTSTAY | MELSSLTSED | TAVYYCTRFY | 100 |
| SYTYWGQGT  | LVTVSSASTKG | PSVFPLAPSS | KSTSGGTAAL | GCLVKDYFPE | 150 |
| PVTVSWNSGA | LTVSGVHTFPA | VLQSSGLYSL | SSVTVTPSSS | LGTQTYICNV | 200 |
| NHKPSNTKVD | KKVEPKSCDK  | THTCPPCPAP | ELLGGPSVFL | FPKPKDTLM  | 250 |
| ISRTPEVTCV | VVDVSHEDPE  | VKFNWYVDGV | EVHNAKTKPR | EEQYNSTYRV | 300 |
| VSVLTVLHQD | WLNKEYKCK   | VSNKALPAPI | EKTISKAKGQ | PREPQVYTLF | 350 |
| PSRDELTKNQ | VSLTCLVKGF  | YPSDIAVEWE | SNGQPENNYK | TTPPVLDSDG | 400 |
| SFFLYSKLTV | DKSRWQQGNV  | FSCSVMEAL  | HNHYTQKSL  | LSPGK      | 445 |

## Light chain / Chaîne légère / Cadena ligera

|            |             |            |            |             |     |
|------------|-------------|------------|------------|-------------|-----|
| DVVMTQSP   | LPVTPGEPAS  | ISCRSSQSLV | HSNRNTYLHW | YLQKPGQSPQ  | 50  |
| LLIYKVSNNR | SGVPDRFSGS  | SGSDFTLKI  | SRVEAEDVGV | YYCSQNTHTVP | 100 |
| PTFGQGT    | IKRTVAAPSV  | FIFPPSDEQL | KSGTASVVC  | LNNFYPREAK  | 150 |
| VQWVKVDNAL | QSGNSQESVTE | QDSKDSSTYS | SSLTSLSKAD | YEKHKVYACE  | 200 |
| VT         | THQGLSSPV   | TKSFNRGEC  |            |             | 219 |

## Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

|                    |         |           |           |           |
|--------------------|---------|-----------|-----------|-----------|
| Intra-H (C23-C104) | 22-96   | 142-198   | 259-319   | 365-423   |
|                    | 22"-96" | 142"-198" | 259"-319" | 365"-423" |

|                    |             |               |
|--------------------|-------------|---------------|
| Intra-L (C23-C104) | 23'-93'     | 139'-199'     |
|                    | 23'''-93''' | 139'''-199''' |

|                        |          |           |
|------------------------|----------|-----------|
| Inter-H-L (h 5-CL 126) | 218-219' | 218"-219" |
|------------------------|----------|-----------|

|                        |          |          |
|------------------------|----------|----------|
| Inter-H-H (h 11, h 14) | 224-224" | 227-227" |
|------------------------|----------|----------|

## N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

295, 295"

## coltuximabum ravtansinum #

## coltuximab ravtansine

immunoglobulin G1-kappa, anti-[*Homo sapiens* CD19 (B lymphocyte surface antigen B4, Leu-12)], chimeric monoclonal antibody conjugated to maytansinoid DM4;  
gamma1 heavy chain (1-450) [*Mus musculus* VH (IGHV1-69\*02 - (IGHD)-IGHJ4\*01) [8.8.13] (1-120) -*Homo sapiens*IGHG1\*01 (CH1 (121-218), hinge (219-233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (223-211')-disulfide with kappa light chain (1'-211') [*Mus musculus* V-KAPPA (IGKV4-70\*01 -IGKJ1\*01) [5.3.7] (1'-104') -*Homo sapiens*IGKC\*01 (105'-211')]; dimer (229-229'':232-232'')-bisdisulfide; conjugated, on an average of 3 to 4 lysyl, to maytansinoid DM4 [*N*<sup>2</sup>-deacetyl-*N*<sup>2</sup>-(4-mercapto-4-methyl-1-oxopentyl)-maytansine] via the reducible SPDB linker [N-succinimidyl 4-(2-pyridylthio)butanoate]  
For the *ravtansine* part, please refer to the document "INN for pharmaceutical substances: Names for radicals, groups and others"

## coltuximab ravtansine

immunoglobuline G1-kappa, anti-[*Homo sapiens* CD19 (antigène de surface B4 des lymphocytes B, Leu-12)], anticorps monoclonal chimérique conjugué au maytansinoïde DM4; chaîne lourde gamma1 (1-450) [*Mus musculus* VH (IGHV1-69\*02 - (IGHD)-IGHJ4\*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1\*01 (CH1 (121-218), charnière (219-233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (223-211')-disulfure avec la chaîne légère kappa (1'-211') [*Mus musculus* V-KAPPA (IGKV4-70\*01 - IGKJ1\*01) [5.3.7] (1'-104') -*Homo sapiens* IGKC\*01 (105'-211')]; dimère (229-229":232-232")-bisdisulfure; conjugué, sur 3 à 4 lysyl en moyenne, au maytansinoïde DM4 [*N*<sup>2</sup>-déacétyl-*N*<sup>2</sup>-(4-mercapto-4-méthyl-1-oxopentyl)-maytansine] via le linker SPDB réductible [4-(2-pyridyldithio)butanoate de *N*-succinimidyle] Pour la partie *ravtansine*, veuillez-vous référer au document "*INN for pharmaceutical substances: Names for radicals, groups and others*".

## coltuximab ravtansina

inmunoglobulina G1-kappa, anti-[CD19 de *Homo sapiens* (antígeno de superficie B4 de los linfocitos B, Leu-12)], anticuerpo monoclonal quimérico conjugado con el maitansinoide DM4; cadena pesada gamma1 (1-450) [*Mus musculus* VH (IGHV1-69\*02 - (IGHD)-IGHJ4\*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1\*01 (CH1 (121-218), bisagra (219-233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (223-211')-disulfuro con la cadena ligera kappa (1'-211') [*Mus musculus* V-KAPPA (IGKV4-70\*01 - IGKJ1\*01) [5.3.7] (1'-104') -*Homo sapiens* IGKC\*01 (105'-211')]; dímero (229-229":232-232")-bisdisulfuro; conjugado en 3 -4 restos lisil por término medio, con el maitansinoide DM4 [*N*<sup>2</sup>-desacetil-*N*<sup>2</sup>-(4-mercapto-4-metil-1-oxopentil)-maitansina] mediante un conector SPDB reducible [4-(2-piridilditio)butanoato de *N*-succinimidilo] La información sobre la *ravtansina*, la encontrarán en el documento "*INN for pharmaceutical substances: Names for radicals, groups and others*".

## Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQPGAE VVKPGASVKL SCKTSGYTFT SNWMHWVKQA PGQGLEWIGE 50
IDPSDSYTNV NQNFQGGAKL TVDKSTSTAY MEVSSLSRDD TAVYVCARGS 100
NPYYAMDIWV GQGTSTVTSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPPTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHPKS NTKVDKKEVP KSCDKHTTCP PCPAPELLGG PSVFLFPPKP 250
KDTLMISRTPEVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTTPV 400
LDSGGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK 450
```

## Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPAI MSASPGERV MTCSASSGVN YMHWYQKPG TSPRRWIYDT 50
SKLASGVPAR FSGSGSGTDY SLTISSMEPE DAATYYCHQR GSYTFGGGTK 100
LEIKRTVAAP SVFIFFPSDE QLKSGTASV CLLNNFYPRE AKVQWQVDNA 150
LQSGNSQESV TEQDSKDSY SLSSITLTSK ADYEKHKVYA CEVTHQGLSS 200
PVTKSFNRGEC 211
```

## Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H (C23-C104) 22-96 147-203 264-324 370-428
                  22"-96" 147"-203" 264"-324" 370"-428"
Intra-L (C23-C104) 23'-87" 131'-191"
                  23"-87'" 131'"-191'"
Inter-H-L (h 5-CL 126) 223-211' 223"-211'"
Inter-H-H (h 11, h 14) 229-229" 232-232"
```

## N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

300, 300"

For the *ravtansine* part, please refer to the document "*INN for pharmaceutical substances: Names for radicals, groups and others*".

Pour la partie *ravtansine*, veuillez vous référer au document "*INN for pharmaceutical substances: Names for radicals, groups and others*".

Para la fracción *ravtansina*, se pueden dirigir al documento "*INN for pharmaceutical substances: Names for radicals, groups and others*".

**damoctocogum alfa pegolum #**  
damoctocog alfa pegol

recombinant DNA derived pegylated B domain deleted human blood coagulation factor VIII (single protein chain) analogue, produced in BHK21 cells (glycoform alfa):

des-(743-1636)-[1804-[S-(1-{3-[(3-{2,3-bis[ω-methoxypoly(oxyethylene)]propoxy}propyl)amino]-3-oxopropyl)-2,5-dioxopyrrolidin-3-yl)-L-cysteine](K>C)]human coagulation factor VIII

## damoctocog alfa pégol

analogue du facteur de coagulation sanguine VIII humain amputé du domaine B (une seule chaîne protéique), produit par des cellules BHK21 à partir d'ADN recombinant (glycoforme alfa) :

dès-(743-1636)-[1804-[S-(1-{3-[(3-{2,3-bis[ω-méthoxypoly(oxyéthylène)]propoxy}propyl)amino]-3-oxopropyl)-2,5-dioxopyrrolidin-3-yl)-L-cystéine](K>C)]facteur VIII de coagulation humain

## damoctocog alfa pegol

análogo del factor VIII de coagulación humano privado del dominio B (una sola cadena proteica), producido por células BHK21 a partir de ADN recombinante (glicoforma alfa) :


des-(743-1636)-[1804-[S-(1-{3-[(3-{2,3-bis[ω-metoxipoli(oxietileno)]propoxi}propil)amino]-3-oxopropil)-2,5-dioxopirrolidin-3-il)-L-cisteina](K>C)]factor VIII de coagulación humano

Single chain protein / Protéine monocaténaire / Proteína monocatenaria (1438 AA)

ATRRYYLGAV ELSWDYMQSD LGELPVDARF PPRVEKSEFP NTSVVYKKTLL 50  
FVEPTDHLFN IAKPRPPWVG LLGPTIQAEV YDVTVTILKN MASHPVSLHA 100  
VGVSYNKASE GAEDDDQTSQ REKEDDKVFP GGSHTYVWQV LKENGPMASD 150  
PLCLTYSYLS HVDLVKDLNS GLIGALLVCR EGS LAKEKTQ TLHKFILLFA 200  
VFDEGKSWHS ETKNLSLMQDR DAASARAWPK MHTVNGYVNR SLPLGLICHR 250  
KSVYVHVGIM GTTPEVHSIF LEGHTFLVRN HRQASLEISP ITFLTAQTLL 300  
MDLGQFLFC HISSHQHDMG EAYVKVDSCP EEPQLRMKN EEAEDYDDL 350  
TDSEMDVVRV DDDNSPFSFIQ IRSVAKKHPK TWVHYIAEE EDWDYAPLVL 400  
APDNRSVKSY YLNNGPQRIG RYKVKVRFFA YTDFTFKTRE AIQHSGLIG 450  
PLLYGEVGDV LLIIFKNQAS RPYNIYPHGI TDVRPLYSRP LPKGVKHLKD 500  
FPILPGEIFK YKWTVTVEDG PTKSDPRCLT RYSSSFVNME RDLASGLIGP 550  
LLICYKESVD QRNGQIMSDG RNVILFSVFD ENRSWYLTEN IQRFLNPAG 600  
VQLEDPEFQA SNIMHSINGY VFDSLQLSVC LHEVAYWYIL SIGAQTDFLS 650  
VFFSGYTFKH KMVEDTLTL FPFSGETVFM SMENPGLWIL GCHNSDFRNR 700  
GMTALLKVSS CDKNTGDIYE DSYEDISAYL LSKNNAIEPR SF 742  
SQNP PVLKRHRQREI 1650  
TRTTLQSDQE EIDYDDTISV EMKKEDFDIY DEDENQSPRS FQKKTTHYFI 1700  
AAVERLDWYG MSSSPHVLRN RAQSGSVQPF KKVVFQEFDT GSFTQPLYRG 1750  
ELNEHLGLLG PYIRAEVEDN IMVTFRNQAS RPYSFYSSLI SYEEDQRQGA 1800  
EPRCNEVFKN ETKTYFWKVQ HHMAPTKDEF DCKAWAYFSD VDLEKDVHSG 1850  
LIGELLVCHT NTLNPAHGRQ VTVQEFALFF TIFDETKSWY FTENMERNCR 1900  
APCNIQMEDP TFKENYRFHA INGYIMDTLF GLVMAQDQRI RWYLLSMGNS 1950  
ENIHSIHFGS HVFTVRKKEE YKMALYNLYP GVFEVTEMLP SKAGIWRVEC 2000  
LIGELHLHAG STFLVLVSNK CQTPLGMASG HIRDFQITAS GOYQGWAPKL 2050  
ARLHYSGSIN AWSTKEPFSW IKVDLLAPMI IHGIKTQGAR QKFSSLYISQ 2100  
FIIMYSLDGK KWQTYRGNST GTLMVFFGNV DSSGIKHNIF NPPIIARYIR 2150  
LHPHYSIRS TLRMELMGCD LNSCSMPLGM ESKAISDAQI TASSYFTNMF 2200  
ATWSPSKARL HLQGRSNAWR PQVNNPKEWL QVDFQKTMKV TGVTTQGVKS 2250  
LLTSMYVKEF LISSSQDGHQ WTLFFQNGKV KVFQGNQDSF TFPVNSLDPP 2300  
LLTRYLRIHP QSWVHQIALR MEVLGCEAQD LY 2332

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro  
153-179 248-329 528-554 630-711 1832-1858 1899-1903 2021-2169 2174-2326

Modified residues / Résidus modifiés / Restos modificados



Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación  
Asn-41 Asn-239 Asn-1810 Asn-2118

**dasabuvirum**

dasabuvir


*N*-(6-{3-*tert*-butyl-5-[2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl]-2-methoxyphenyl}naphthalen-2-yl)methanesulfonamide

dasabuvir

*N*-(6-{3-*tert*-butyl-5-[2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl]-2-méthoxyphényl}naphtalén-2-yl)méthanesulfonamide

dasabuvir

*N*-(6-{3-*terc*-butil-5-[2,4-dioxo-3,4-dihidropirimidin-1(2*H*)-il]-2-metoxifenil}naftalen-2-il)metanosulfonamida

C<sub>26</sub>H<sub>27</sub>N<sub>3</sub>O<sub>5</sub>S**decoglurantum**

decoglurant


5-[2-[7-(trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-*a*]pyrimidin-3-yl]ethynyl]pyridin-2-amine

décoglurant

5-(2-[7-(trifluorométhyl)-5-[4-(trifluorométhyl)phényl]pyrazolo[1,5-*a*]pyrimidin-3-yl]éthynyl)pyridin-2-amine

decoglurant

5-(2-[7-(trifluorometil)-5-[4-(trifluorometil)fenil]pirazolo[1,5-*a*]pirimidin-3-il]etinil)piridin-2-amina

C<sub>21</sub>H<sub>11</sub>F<sub>6</sub>N<sub>5</sub>**dianexinum #**

dianexin

recombinant DNA derived annexin A5 dimer covalently linked by a 14 residues peptide linker, produced in *Escherichia coli* (nonglycosylated):

L-methionyl-human annexin A5 fusion protein with glycyl-L-seryl-L-leucyl-L-α-glutamyl-L-valyl-L-leucyl-L-phenylalanyl-L-glutaminyglycyl-L-prolyl-L-serylglycyl-L-lysyl-L-leucyl-human annexin A5

dianexine

dimère de l'annexine A5 liées de façon covalente par une chaîne peptidique de 14 acides aminés, produit par *Escherichia coli* à partir d'ADN recombinant (non glycosylé) :

L-méthionyl-annexine A5 humaine protéine de fusion avec la glycyl-L-séryl-L-leucyl-L-α-glutamyl-L-valyl-L-leucyl-L-phénylalaninyl-L-glutaminyglycyl-L-prolyl-L-sérylglycyl-L-lysyl-L-leucyl-annexine A5 humaine

dianexina

dímero de la anexina A5 covalentemente unido por una cadena peptídica de 14 aminoácidos, producido por *Escherichia coli* a partir de ADN recombinante (no glicosilado) :  
L-metionil-anexina A5 humana proteína de fusión con la glicil-L-seril-L-leucil-L- $\alpha$ -glutamil-L-valil-L-leucil-L-fenilalanil-L-glutaminilglicil-L-prolil-L-serilglicil-L-lisil-L-leucil-anexina A5 humana

## Sequence / Séquence / Secuencia


```

MAQVLRGTVT DFPGFDERAD AETLRKAMKG LGTDEESILT LLTSRSNAQR 50
QEISAFAKTL FGRDLLDDLK SELTGKFEKL IVALMKPSRL YDAYELKHAL 100
KGAGTNEKVL TEIIASRTP EELRAIKQVYE EEYSSSLEDD VVGDTSGYYQ 150
RMLVLLQAN RDPDAGIDEA QVEQDAQALF QAGELKWGTD EEKFITIFGT 200
RSVSHLRKVF DKYMTISGFQ IEETIDRETS GNLEQLLLAV VKSIRSIPAY 250
LAETLYYAMK GAGTDDHTLI RVMVSRSEID LFNIRKEFRK NFATSLYSMI 300
KGDTSQGYKK ALLLLCGEDD GSLEVLFGQP SGKLAQVLRG TVTDFPGFDE 350
RADAETLRKA MKGLGTDEES ILTLTSSRSN AQRQEISAAF KTLFGRDLLD 400
DLKSELTKGF EKLIVALKMP SRLYDAYELK HALKGAGTNE KVLTEIASR 450
TPEELRAIKQ VYEEYGSSE EDDVVGDTSG YYQRMLVLL QANRDPDAGI 500
DEAQVEQDAQ ALFQAGELKW GTDEEKFITI FGTRSVSHLR KVFDKYMTIS 550
GFQIEETIDR ETSGNLEQLL LAVVKSIRSI PAYLAETLYY AMKGAGTDDH 600
TLIRVMVSR S EIDLFNIRKE FRKNFATSLY SMIKGDTSQD YKKALLLLCG 650
EDD


```

## Modified residues / Résidus modifiés / Restos modificados

K = N<sup>6</sup>-acetylLys  
70-76-79-97-101-403-409-412-430-434



Y = phosphoTyr  
94-427



dinutuximabum #  
dinutuximab

immunoglobulin G1-kappa, anti-ganglioside GD2, chimeric monoclonal antibody;  
gamma1 heavy chain (1-443) [*Mus musculus* VH (IGHV1S135\*01 - (IGHD)-IGHJ4\*01) [8.8.6] (1-113) -*Homo sapiens* IGHG1\*03 (CH1 (114-211), hinge (212-226), CH2 (227-336), CH3 (337-441), CHS (442-443)) (114-443)], (216-220')-disulfide with kappa light chain (1'-220') [*Mus musculus* V-KAPPA (IGKV1-110\*01 - IGKJ5\*01) 11.3.10] (1'-113') -*Homo sapiens* IGKC\*01 (114'-220'')]; dimer (222-222'':225-225'')-bisdisulfide

dinutuximab

immunoglobuline G1-kappa, anti-ganglioside GD2, anticorps monoclonal chimérique;  
chaîne lourde gamma1 (1-443) [*Mus musculus* VH (IGHV1S135\*01 - (IGHD)-IGHJ4\*01) [8.8.6] (1-113) -*Homo sapiens* IGHG1\*03 (CH1 (114-222), charnière (223-237), CH2 (238-347), CH3 (348-452), CHS (453-454)) (125-454)], (216-220')-disulfure avec la chaîne légère kappa (1'-220') [*Mus musculus* V-KAPPA (IGKV1-110\*01 - IGKJ5\*01) 11.3.10] (1'-113') -*Homo sapiens* IGKC\*01 (114'-220'')]; dimère (222-222'':225-225'')-bisdisulfure

dinutuximab

inmunoglobulina G1-kappa, anti-gangliósido GD2, anticuerpo monoclonal quimérico;  
cadena pesada gamma1 (1-443) [*Mus musculus* VH (IGHV1S135\*01 - (IGHD)-IGHJ4\*01) [8.8.6] (1-113) -*Homo sapiens* IGHG1\*03 (CH1 (114-222), bisagra (223-237), CH2 (238-347), CH3 (348-452), CHS (453-454)) (125-454)], (216-220')-disulfuro con la cadena ligera kappa (1'-220') [*Mus musculus* V-KAPPA (IGKV1-110\*01 - IGKJ5\*01) 11.3.10] (1'-113') -*Homo sapiens* IGKC\*01 (114'-220'')]; dímero(222-222'':225-225'')-bisdisulfuro


|   |             |               |            |
|---|-------------|---------------|------------|
| Heavy chain / Chaîne lourde / Cadena pesada   |             |               |            |
| EVQLLQSGPE  | LEKPGASVMI  | SCKASGSSFT    | GYNMNWVRQN |
| IDPYYGGTSY  | NQKFKGRATL  | TVDKSSSTAY    | MHLKSLTSED |
| EYWGGQTSVT  | VSSASTKGPS  | VFPLAPSSKS    | TSGGTAALGC |
| TVSWNSGALT  | SGVHTFPAVL  | QSSGLYSLSS    | VVTVPSSSLG |
| KPSNTKVDKR  | VEPKSCDKTH  | TCPPCPAPEL    | LGGPSVFLFP |
| RTPEVTCVVV  | DVSHEDPEVK  | FNWYVDGVEV    | HNAKTKPREE |
| VLTVLHQDWL  | NGKEYCKKVS  | NKALPAPIEK    | TISKAKGQPR |
| REEMTKNQVS  | LTCLVKGFYP  | SDIAVEWESN    | GQPENNYKTT |
| FLYSKLTVDK  | SRWQQGNVFS  | CSVMHEALHN    | HYTQKSLSLG |
| PGK   |             |               | 443        |
| Light chain / Chaîne légère / Cadena ligera   |             |               |            |
| EIVMTQSPAT  | LSVSPGERAT  | LSCRSSQSLV    | HRNGNTYLHW |
| LLIHKVSNRF  | SGVPDRFSGS  | GSGETDTLKI    | SRVEAEDLGV |
| PLTFGAGTKL  | ELKRTVAAPS  | VFIFPPSDEQ    | LKSGTASVVC |
| KVQWKVDNAL  | QSGNSQESVT  | EQDSKDSITYS   | LSSTLTLSKA |
| EVTHQGLSSP  | VTKSFNRGEC  |               | 220        |
| Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro |             |               |            |
| Intra-H (C23-C104)  | 22-96       | 140-196       | 257-317    |
|   | 22"-96"     | 140"-196"     | 257"-317"  |
| Intra-L (C23-C104)  | 23'-93'     | 140'-200'     |            |
|   | 23'''-93''' | 140'''-200''' |            |
| Inter-H-L (h 5-CL 126)  | 216-220'    | 216"-220"     |            |
| Inter-H-H (h 11-h 14)   | 222-222"    | 225-225"      |            |
| N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación                |             |               |            |
| H CH2 N84.4:  |             |               |            |
| 293, 293"   |             |               |            |

**doravirinum**  
doravirine

3-chloro-5-({1-[(4-methyl-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl}oxy)benzonitrile

3-chloro-5-({1-[(4-méthyl-5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-3-yl)méthyl]-2-oxo-4-(trifluorométhyl)-1,2-dihydropyridin-3-yl}oxy)benzonitrile

3-cloro-5-({1-[(4-metil-5-oxo-4,5-dihidro-1*H*-1,2,4-triazol-3-il)metil]-2-oxo-4-(trifluorometil)-1,2-dihidropiridin-3-il}oxi)benzonitrilo



**eldelumabum #**  
eldelumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* CXCL10 (chemokine C-X-C motif ligand 10, 10 kDa interferon gamma-induced protein gamma-IP10, IP-10, INP10, small inducible cytokine B10, SCYB10)], *Homo sapiens* monoclonal antibody;gamma1 heavy chain (1-454) [*Homo sapiens* VH (IGHV3-33\*01 (89.80%) -(IGHD)-IGHJ6\*01) [8.8.17] (1-124) -IGHG1\*01 (CH1 (125-222), hinge (223-237), CH2 (238-347), CH3 (348-452), CHS (453-454)) (125-454)], (227-216')-disulfide with kappa light chain (1'-216') [*Homo sapiens* V-KAPPA (IGKV3-20\*01 (100.00%) -IGKJ3\*01) [7.3.10] (1'-109') -IGKC\*01 (110'-216')]; dimer (233-233":236-236")-bisdisulfide

**eldélumab**

immunoglobuline G1-kappa, anti-[*Homo sapiens* CXCL10 (chémokine C-X-C motif ligand 10, protéine gamma-IP10 de 10 kDa induite par l'interféron gamma, IP-10, INP10, petite cytokine inductible B10, SCYB10)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-454) [*Homo sapiens* VH (IGHV3-33\*01 (89.80%) -(IGHD)-IGHJ6\*01) [8.8.17] (1-124) -IGHG1\*01 (CH1 (125-222), charnière (223-237), CH2 (238-347), CH3 (348-452), CHS (453-454)) (125-454)], (227-216')-disulfure avec la chaîne légère kappa (1'-216') [*Homo sapiens* V- KAPPA (IGKV3-20\*01 (100.00%) -IGKJ3\*01) [7.3.10] (1'-109') -IGKC\*01 (110'-216')]; dimère (233-233":236-236")-bisdisulfure

**eldelumab**

immunoglobulina G1-kappa, anti-[CXCL10 de *Homo sapiens* (quimioquina C-X-C motivo ligando 10, proteína gamma-IP10 de 10 kDa inducida por el interferón gamma, IP-10, INP10, pequeña citoquina inducible B10, SCYB10)], anticuerpo monoclonal de *Homo sapiens*; cadena pesada gamma1 (1-454) [*Homo sapiens* VH (IGHV3-33\*01 (89.80%) -(IGHD)-IGHJ6\*01) [8.8.17] (1-124) -IGHG1\*01 (CH1 (125-222), bisagra (223-237), CH2 (238-347), CH3 (348-452), CHS (453-454)) (125-454)], (227-216')-disulfuro con la cadena ligera kappa (1'-216') [*Homo sapiens* V-KAPPA (IGKV3-20\*01 (100.00%) -IGKJ3\*01) [7.3.10] (1'-109') -IGKC\*01 (110'-216')]; dímero (233-233":236-236")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

|            |            |            |            |            |     |
|------------|------------|------------|------------|------------|-----|
| QMQLVESGGG | VVQPGRLRL  | SCTASGFTFS | NNGMHVVRQA | PGKGLEWVAV | 50  |
| IWFDMGNKFI | VDSVKGRFTI | SRDNSKNTLY | LEMNSLRAED | TAIYYCAREG | 100 |
| DGSGIYYFYG | MDVWGQGTIV | TVSSASTKGP | SVEFLAPSSK | STSGGTAALG | 150 |
| CLVKDYFPEP | VTVSWNSGAL | TSGVHTFPAV | LQSSGLYSL  | SVTVTPSSSL | 200 |
| GTQTYICNVN | HKPSNTKVDK | RVEPKSCDKT | HTCPPCPAPE | LLGGPSVFLF | 250 |
| PPKPKDTLMI | SRTPEVTCVV | VDVSHEDPEV | KFNWYVDGVE | VHNAKTKPRE | 300 |
| EQYNSTYRVV | SVLTVLHQDW | LNGKEYKCKV | SNKALPAPIE | KTISKAKGQP | 350 |
| REPQVYTLPP | SREEMTKNQV | SLTCLVKGFY | PSDIAVEWES | NGQPENNYKT | 400 |
| TPPVLDSDGS | FFLYSKLTVD | KSRWQQGNVF | SCSVMEALH  | NHYTQKSLSL | 450 |
| SPGK       |            |            |            |            | 454 |

Light chain / Chaîne légère / Cadena ligera

|            |            |            |            |            |     |
|------------|------------|------------|------------|------------|-----|
| EIVLTQSPGT | LSLSPGERAT | LSCRASQSVS | SSYLAWYQQK | PGQAPRLLIY | 50  |
| GASSRATGIP | DRFSGSGSGT | DFTLTISRLE | PEDFAVYYCQ | QYGSPIPTFF | 100 |
| GPSTKVDIKR | TVAAPSVEFI | PSDEQLKSG  | TASVVCLLNN | FYPREAKVQW | 150 |
| KVDNALQSGN | SOESVTEQDS | KDSTYLSST  | LTLKADYEK  | HKVYACEVTH | 200 |
| QGLSSPVTKS | FNRGEC     |            |            |            | 216 |

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

|                        |           |           |           |           |
|------------------------|-----------|-----------|-----------|-----------|
| Intra-H (C23-C104)     | 22"-96"   | 151"-207" | 268"-328" | 374"-432" |
| Intra-L (C23-C104)     | 23'-89"   | 136"-196" |           |           |
| Inter-H-L (h 5-CL 126) | 227"-216" | 227"-216" |           |           |
| Inter-H-H (h 11, h 14) | 233-233"  | 236-236"  |           |           |

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación  
H CH2 N84.4:  
304, 304"

**eluxadolinum**  
eluxadoline

5-(((2S)-2-amino-3-(4-carbamoyl-2,6-dimethylphenyl)propanoyl)[(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino)methyl)-2-methoxybenzoic acid


éluxadoline

acide 5-(((2S)-2-amino-3-(4-carbamoyl-2,6-diméthylphényl)propanoyl)[(1S)-1-(4-phényl-1H-imidazol-2-yl)éthyl]amino)méthyl)-2-méthoxybenzoïque

eluxadolina

ácido 5-(((2S)-2-amino-3-(4-carbamoyl-2,6-dimetilfenil)propanoil)[(1S)-1-(4-fenil-1H-imidazol-2-il)etil]amino)metil)-2-metoxibenzoico



$C_{32}H_{35}N_5O_5$ 

**encorafenibum**  
encorafenib


methyl *N*-{[(2*S*)-1-[(4-{3-[5-chloro-2-fluoro-3-(methanesulfonamido)phenyl]]-1-(propan-2-yl)-1*H*-pyrazol-4-yl}pyrimidin-2-yl)amino]propan-2-yl}carbamate

encorafénib

*N*-{[(2*S*)-1-[(4-{3-[5-chloro-2-fluoro-3-(méthanesulfonamido)phényl]]-1-(propan-2-yl)-1*H*-pyrazol-4-yl}pyrimidin-2-yl)amino]propan-2-yl}carbamate de méthyle

encorafenib

*N*-{[(2*S*)-1-[(4-{3-[5-cloro-2-fluoro-3-(metanosulfonamido)fenil]]-1-(propan-2-il)-1*H*-pirazol-4-il}pirimidin-2-il)amino]propan-2-il}carbamato de metilo

 $C_{22}H_{27}ClFN_7O_4S$ 

**enfortumabum vedotinum #**  
enfortumab vedotin

immunoglobulin G1-kappa, anti-[*Homo sapiens* PVRL4 (poliovirus receptor-related 4, nectin-4, nectin 4, PPR4, LNIR), *Homo sapiens* monoclonal antibody conjugated to auristatin E; gamma1 heavy chain (1-447) [*Homo sapiens* VH (IGHV3-48\*02 (98.00%) -(IGHD)-IGHJ6\*01 [8.8.10] (1-117) -IGHG1\*03 (CH1 (118-215), hinge (216-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-12\*01 (96.80%) -IGKJ4\*01 [6.3.9] (1'-107') -IGKC\*01 (108'-214'))]; dimer (226-226":229-229")-bisdisulfide; conjugated, on an average of 3 to 4 cysteinyl, to monomethylauristatin E (MMAE), via a cleavable maleimidecaproyl-valyl-citrullinyl-*p*-aminobenzylcarbamate (mc-val-cit-PABC) linker For the *vedotin* part, please refer to the document "*INN for pharmaceutical substances: Names for radicals, groups and others*".

## enfortumab védotine

immunoglobuline G1-kappa, anti-[*Homo sapiens* PVRL4 (membre 4 de la famille du récepteur du poliovirus, nectine-4, nectine 4, PPR4, LNIR), *Homo sapiens* anticorps monoclonal conjugué à l'auristatine E; chaîne lourde gamma1 (1-447) [*Homo sapiens* VH (IGHV3-48\*02 (98.00%) -(IGHD)-IGHJ6\*01) [8.8.10] (1-117) -IGHG1\*03 (CH1 (118-215), charnière (216-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V- KAPPA (IGKV1-12\*01 (96.80%) -IGKJ4\*01) [6.3.9] (1'-107') -IGKC\*01 (108'-214')]; dimère (226-226'':229-229'')-bisdisulfure; conjugué, sur 3 à 4 cystéinyl en moyenne, au monométhylauristatine E (MMAE), via un linker clivable maléimidecaproyl-valyl-citrullinyl-*p*-aminobenzylcarbamate (mc-val-cit-PABC)

Pour la partie *védotine*, veuillez-vous référer au document "*INN for pharmaceutical substances: Names for radicals, groups and others*".

## enfortumab vedotina

inmunoglobulina G1-kappa, anti-[PVRL4 de *Homo sapiens* (miembro 4 de la familia del receptor de poliovirus, nectina-4, nectina 4, PPR4, LNIR), anticuerpo monoclonal de *Homo sapiens* conjugado con auristatina E;

cadena pesada gamma1 (1-447) [*Homo sapiens* VH (IGHV3-48\*02 (98.00%) -(IGHD)-IGHJ6\*01) [8.8.10] (1-117) -IGHG1\*03 (CH1 (118-215), bisagra(216-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-12\*01 (96.80%) -IGKJ4\*01) [6.3.9] (1'-107') -IGKC\*01 (108'-214')]; dímero (226-226'':229-229'')-bisdisulfuro; conjugado, en 3- 4 restos cisteinil por término medio, con monometilauristatina E (MMAE), mediante un conector escindible maleimidocaproil-valil-citrulinil-*p*-aminobencilcarbamato (mc-val-cit-PABC)

La información sobre la *vedotina*, la encontrarán en el documento "*INN for pharmaceutical substances: Names for radicals, groups and others*".

Heavy chain / Chaîne lourde / Cadena pesada  
EVQLVESGGG LVQPGGSLRL SCAASGFTFS SYNMNWRQA PGKLEWVSY 50  
ISSSSSTIYY ADSVKGRTI SRDANKSL LQNSLRDED TAVYYCARAY 100  
YYGMDVWGQG TTVTVSSAST KGPSVFPLAP SSKTSGGTA ALGCLVKDYF 150  
PEPTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVTVPS SSLGTQTYIC 200  
NVNHKPSNTK VDKRVEPKSC DKHTCCPCP APELLGGPSV FLFPPKPKDT 250  
LMISRTPEVT CVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300  
RVVSVLTVLH QDWLNKEYK CKVSNKALPA PIEKTSKAK GPPEPQVYT 350  
LPFSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTTPVLDL 400  
DGSFFLYSKL TVDKSRWQGG NVFSCSMHE ALHNHYTQKS LSLSPGK 447

Light chain / Chaîne légère / Cadena ligera  
DIQMTQSPSS VSASVGRVIT ITCRASQGIS GWLAWYQQK GKAPKFLIYA 50  
ASTLQSGVPS RFGSGSGSTD FTLTISSLQP EDFATYCCQ ANSFPTFGG 100  
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNFF PREAKVQWVK 150  
DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYEKKH VYACEVTHQG 200  
LSSPVTGSFN RGEC 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22'-96" 144"-200" 261'-321" 367'-425"  
22'-96" 144"-200" 261'-321" 367'-425"

Intra-L (C23-C104) 23'-88" 134"-194"  
23'-88" 134"-194"

Inter-H-L (h 5-CL 126) \* 220'-214' 220'-214"

Inter-H-H (h 11, h 14) \* 226'-226" 229'-229"

\*Two or three of the inter-chain disulfide bridges are not present, an average of 3 to 4 cysteinyl being conjugated each to a drug linker.

\*Deux ou trois des ponts disulfures inter-chaînes ne sont pas présents, 3 à 4 cystéinyl en moyenne étant chacun conjugué à un linker-principe actif.

\*Faltan dos o tres puentes disulfuro inter-catenarios, una media de 3 a 4 cisteinil está conjugada a conectores de principio activo.

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:  
297, 297"

For the vedotin part, please refer to the document "*INN for pharmaceutical substances:*

*Names for radicals, groups and others*".

Pour la partie *védotine*, veuillez vous référer au document "*INN for pharmaceutical*

*substances: Names for radicals, groups and others*".

Para la fracción *vedotina*, se pueden dirigir al documento "*INN for pharmaceutical*

*substances: Names for radicals, groups and others*".

**fevipiprantum**


fevipiprant

2-(1-([4-methanesulfonyl-2-(trifluoromethyl)phenyl]methyl)-2-methyl-1*H*-pyrrolo[2,3-*b*]pyridin-3-yl)acetic acid

févipiprant

acide 2-(1-([4-méthanesulfonyl-2-(trifluorométhyl)phényl]méthyl)-2-méthyl-1*H*-pyrrolo[2,3-*b*]pyridin-3-yl)acétique

fevipiprant

ácido 2-(1-([4-metanosulfonil-2-(trifluorometil)fenil]metil)-2-metil-1*H*-pirrolo[2,3-*b*]piridin-3-il)acéticoC<sub>19</sub>H<sub>17</sub>F<sub>3</sub>N<sub>2</sub>O<sub>4</sub>S**filanesibum**


filanesib

(2*S*)-2-(3-aminopropyl)-5-(2,5-difluorophenyl)-*N*-methoxy-*N*-methyl-2-phenyl-1,3,4-thiadiazole-3(2*H*)-carboxamide

filanésib

(2*S*)-2-(3-aminopropil)-5-(2,5-difluorophényl)-*N*-méthoxy-*N*-méthyl-2-phényl-1,3,4-thiadiazole-3(2*H*)-carboxamide

filanesib

(2*S*)-2-(3-aminopropil)-5-(2,5-difluorofenil)-2-fenil-*N*-metil-*N*-metoxi-1,3,4-tiadiazol-3(2*H*)-carboxamidaC<sub>20</sub>H<sub>22</sub>F<sub>2</sub>N<sub>4</sub>O<sub>2</sub>S**galunisertibum**


galunisertib

4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4*H*-pyrrolo[1,2-*b*]pyrazol-3-yl]quinoline-6-carboxamide

galunisertib

4-[2-(6-méthylpyridin-2-yl)-5,6-dihydro-4*H*-pyrrolo[1,2-*b*]pyrazol-3-yl]quinoléine-6-carboxamide

galunisertib

4-[2-(6-metilpiridin-2-il)-5,6-dihidro-4*H*-pirrolo[1,2-*b*]pirazol-3-il]quinolina-6-carboxamidaC<sub>22</sub>H<sub>19</sub>N<sub>5</sub>O

**guselkumabum #**

guselkumab

immunoglobulin G1-lambda2, anti-[*Homo sapiens* IL23 (interleukin 23, IL-23)], *Homo sapiens* monoclonal antibody;  
gamma1 heavy chain (1-446) [*Homo sapiens* VH (IGHV5-51\*01 (93.90%) -(IGHD)-IGHJ3\*01 M123>L (112)) [8.8.10] (1-117) -IGHG1\*01 (CH1 (118-215), hinge (216-230), CH2 (231-340), CH3 (341-444), CHS (445-446)) (118-446)], (220-216')-disulfide with lambda light chain (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-40\*01 (91.80%) -IGLJ2\*01) [9.3.11] (1'-111') -IGLC2\*01 (112'-217')]; dimer (226-226":229-229")-bisdisulfide

guselkumab

immunoglobuline G1-lambda2, anti-[*Homo sapiens* IL23 (interleukine 23, IL-23)], *Homo sapiens* anticorps monoclonal;  
chaîne lourde gamma1 (1-446) [*Homo sapiens* VH (IGHV5-51\*01 (93.90%) -(IGHD)-IGHJ3\*01 M123>L (112)) [8.8.10] (1-117) -IGHG1\*01 (CH1 (118-215), charnière (216-230), CH2 (231-340), CH3 (341-444), CHS (445-446)) (118-446)], (220-216')-disulfure avec la chaîne légère lambda (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-40\*01 (91.80%) -IGLJ2\*01) [9.3.11] (1'-111') -IGLC2\*01 (112'-217')]; dimère (226-226":229-229")-bisdisulfure

guselkumab

immunoglobulina G1-lambda2, anti-[IL23 (interleukina 23, IL-23) de *Homo sapiens*], anticuerpo monoclonal de *Homo sapiens*;  
cadena pesada gamma1 (1-446) [*Homo sapiens* VH (IGHV5-51\*01 (93.90%) -(IGHD)-IGHJ3\*01 M123>L (112)) [8.8.10] (1-117) -IGHG1\*01 (CH1 (118-215), bisagra (216-230), CH2 (231-340), CH3 (341-444), CHS (445-446)) (118-446)], (220-216')-disulfuro con la cadena ligera lambda (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-40\*01 (91.80%) -IGLJ2\*01) [9.3.11] (1'-111') -IGLC2\*01 (112'-217')]; dímero (226-226":229-229")-bisdisulfuro

## Heavy chain / Chaîne lourde / Cadena pesada

|             |            |            |            |             |     |
|-------------|------------|------------|------------|-------------|-----|
| EVQLVQSGAE  | VKKPGESLKI | SCKGSQSYFS | NYWIGWVRQM | PGKGLEWMI   | 50  |
| IDPSNSYTRY  | SPSFQGVVTI | SADKSISTAY | LQWSSLKASD | TAMYICARWY  | 100 |
| YKPFQVWGQG  | TLVTVSSAST | KGPSVFPLAP | SSKSTSGGTA | ALGCLVKDYF  | 150 |
| PEPFTVSWNS  | GALTSGVHTF | PAVLQSSGLY | SLSSVTVVPS | SSLGTQTYIC  | 200 |
| NVNHKPSNTK  | VDKKVEPKSC | DKTHTCPPCP | APELLGGPSV | FLFPPPKPKDT | 250 |
| LMISRTPEVT  | CVVVDVSHED | PEVKFNWYVD | GVEVHNAKTK | PREEQYNSTY  | 300 |
| RVVSVLTIVLH | QDWLNGKEYK | CKVSNKALPA | PIEKTISKAK | GQPREPQVYT  | 350 |
| LPSPSRDELTK | NQVSLTCLVK | GFYPSTDAVE | WESNGQPENN | YKTTTPPVLD  | 400 |
| DGSFFLYSKL  | TVDKSRWQQG | NVFSCSVMEH | ALHNHYTQKS | LSLSPG      | 446 |

## Light chain / Chaîne légère / Cadena ligera

|            |            |            |            |            |     |
|------------|------------|------------|------------|------------|-----|
| QSVLTQPPSV | SGAPGQRVTI | SCTGSSSNIG | SGYDVHWYQQ | LPGTAPKLLI | 50  |
| YGNKRPSGV  | PDRFSGSKSG | TSASLAITGL | QSEDEADYYC | ASWTDGLSLV | 100 |
| VFGGQTKLTV | LQQPKAAPSV | TLFPPSSEEL | QANKATLVCL | ISDFYPGAVT | 150 |
| VAKADSSPV  | KAGVETTPFS | KQSNNKYAAS | SYLSLTPEQW | KSHRSYSCQV | 200 |
| THEGSTVEKT | VAPTECS    |            |            |            | 217 |

## Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

|                    |         |           |           |           |
|--------------------|---------|-----------|-----------|-----------|
| Intra-H (C23-C104) | 22-96   | 144-200   | 261-321   | 367-425   |
|                    | 22"-96" | 144"-200" | 261"-321" | 367"-425" |

|                    |             |               |
|--------------------|-------------|---------------|
| Intra-L (C23-C104) | 22'-90'     | 139'-198'     |
|                    | 22'''-90''' | 139'''-198''' |

|                        |          |           |
|------------------------|----------|-----------|
| Inter-H-L (h 5-CL 126) | 220-216' | 220"-216" |
|------------------------|----------|-----------|

|                        |          |          |
|------------------------|----------|----------|
| Inter-H-H (h 11, h 14) | 226-226" | 229-229" |
|------------------------|----------|----------|

## N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

297, 297"

**idarucizumabum #**

idarucizumab

immunoglobulin Fab G1-kappa, anti-[dagibatran], humanized monoclonal antibody;  
VH-(CH1-hinge) gamma1 heavy chain (1-225) [humanized VH (*Homo sapiens* IGHV4-59\*01 (82.30%) -(IGHD)-IGHJ4\*01) [8.7.16] (1-122) -*Homo sapiens* IGHG1\*01 (CH1 (123-220), hinge 1-5 (221-225)) (123-225)], (225-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens* IGKV2-30\*01 (88.00%) -IGKJ4\*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC\*01 (113'-219')]

|                              |  |
|------------------------------|--|
| idarucizumab                 | immunoglobuline Fab G1-kappa, anti-[dagibatran], anticorps monoclonal humanisé;<br>chaîne lourde VH-(CH1-charnière) gamma1 (1-225) [VH humanisé ( <i>Homo sapiens</i> IGHV4-59*01 (82.30%) -(IGHD)-IGHJ4*01) [8.7.16] (1-122) - <i>Homo sapiens</i> IGHG1*01 (CH1 (123-220), charnière 1-5 (221-225)) (123-225)], (225-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé ( <i>Homo sapiens</i> IGKV2-30*01 (88.00%) -IGKJ4*01) [11.3.9] (1'-112') - <i>Homo sapiens</i> IGKC*01 (113'-219')]   |
| idarucizumab                 | immunoglobulina Fab G1-kappa, anti-[dagibatrán], anticuerpo monoclonal humanizado;<br>cadena pesada VH-(CH1-bisagra) gamma1 (1-225) [VH humanizado ( <i>Homo sapiens</i> IGHV4-59*01 (82.30%) -(IGHD)-IGHJ4*01) [8.7.16] (1-122) - <i>Homo sapiens</i> IGHG1*01 (CH1 (123-220), bisagra 1-5 (221-225)) (123-225)], (225-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizado ( <i>Homo sapiens</i> IGKV2-30*01 (88.00%) -IGKJ4*01) [11.3.9] (1'-112') - <i>Homo sapiens</i> IGKC*01 (113'-219')] |
|                              | Heavy chain / Chaîne lourde / Cadena pesada<br>QVQLQESGPG LVKPSSETLSL TCTVSGFSLT SYIVDWIRQP PGKGLEWIGV 50<br>IWAGGSTGYN SALRSRVSIT KDTSKNQFSL KLSSVTAADT AVYYCASAAY 100<br>YSYINYDGFA YWQGTLVTV SSASTKGPSV FFLAPSSKST SGGTAALGCL 150<br>VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTPSSSLGT 200<br>QTYICNVNHK PSNTKVDKKV EPKSC 225   |
|                              | Light chain / Chaîne légère / Cadena ligera<br>DVVMTQSPLS LPVTLGQPAS ISCKSSQSL YTDGKTYLYW FLQRFQSPR 50<br>RLIYLVSCLD SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCQSTHFP 100<br>HTPFGGSKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150<br>VQWKVDNALQ SGNSQESVTE QDSKDYSTSL SSTLTLSKAD YEKHKVYACE 200<br>VTHQGLSPV TKSFNREGC 219   |
|                              | Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro<br>Intra-H (C23-C104) 22-95 149-205<br>Intra-L (C23-C104) 23'-93' 139'-199'<br>Inter-H-L (h 5-CL 126) 225-219'   |
|                              | N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación<br>None - Aucun - Ninguno   |
| ipafriceptum #<br>ipafricept | fusion protein for immune applications (FPIA) comprising <i>Homo sapiens</i> FZD8 (frizzled family receptor 8, Frizzled-8) extracellular domain, fused with <i>Homo sapiens</i> immunoglobulin G1 Fc fragment; <i>Homo sapiens</i> FZD8 precursor fragment 28-158 (1-131) - <i>Homo sapiens</i> IGHG1*01 H-CH2-CH3 fragment (hinge 1-15 C5>S (136) (132-146), CH2 (147-256), CH3 (257-361), CHS (362-363)) (132-363); dimer (142-142':145-145')-bisdisulfide   |
| ipafricept                   | protéine de fusion pour applications immunitaires (FPIA) comprenant le domaine extracellulaire d' <i>Homo sapiens</i> FZD8 (membre 8 de la famille de récepteurs frizzled, Frizzled-8), fusionné au fragment Fc de l' <i>Homo sapiens</i> immunoglobuline G1; <i>Homo sapiens</i> FZD8 fragment 28-158 du précurseur (1-131) - <i>Homo sapiens</i> IGHG1*01 fragment H-CH2-CH3 (charnière 1-15 C5>S (136) (132-146), CH2 (147-256), CH3 (257-361), CHS (362-363)) (132-363); dimère (142-142':145-145')-bisdisulfure |

## ipafricept

proteína de fusión para aplicaciones inmunitarias (que comprende el dominio extracelular de FZD8 de *Homo sapiens* (miembro 8 de la familia de receptores frizzled, Frizzled-8), fusionado con el fragmento Fc de inmunoglobulina G1 de *Homo sapiens*; fragmento precursor 28-158 (1-131) de FZD8 de *Homo sapiens* - *Homo sapiens* IGHG1\*01 fragmento H-CH2-CH3 (bisagra 1-15 C5>S (136) (132-146), CH2 (147-256), CH3 (257-361), CHS (362-363)) (132-363); dímero(142-142':145-145')-bisdisulfuro

## Fused chain / chaîne fusionnée / cadena fusionada

```

ASAKELACQE  ITVPLCKGIG  YNYTYMPNQF  NHDQTQDEAGL  EVHQFWPLVE  50
IQCSFDLKFF  LCSMYTPICL  EDYKKPLPPC  RSVCKERAKAG  CAPLMRQYGF  100
AWPDRMRCDR  LPEQGNPDTL  CMDYNRTDLT  TEPKSSDKTH  TCPPCPAPEL  150
LGGPSVFLFP  PKPKDTLMIS  RTEVTCVVV  DVSHEDEPVK  FNWYVDGVEV  200
HNATKPREE  QNSTYRVVS  VLTVLHQDWL  NGKEYCKVVS  NKALPAPIEK  250
TISKAKGQPR  EPQVYTLPPS  RDELTKQVVS  LTCLVKGFYF  SDIAVEWESN  300
GQPENNYKTT  PPVLDSGGSF  FLYSKLTVDK  SRWQQGNVFS  CSVMHEALHN  350
HYTKSLSL  PGK  363

```

## Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```

Intrachain  FZD8      8-69  16-62  53-91  80-121  84-108
              8'-69' 16'-62' 53'-91' 80'-121' 84'-108'
              C23-C104  177-237  283-341
              177'-237' 283'-341'
Interchain  h 11, h 14  142-142' 145-145'

```

## N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

22, 125, 22', 125': bi-, tri- and tetra-antennary oligosaccharides containing up to 4 sialic acids  
213, 213' (CH2 N84.4): complex biantennary oligosaccharide

Post-translational modifications/ modifications post-traductionnelles / modificaciones post-traduccionales  
363, 363': C-terminal K processed by carboxypeptidase-like activity

## ledipasvirum

## ledipasvir

methyl [(1*S*)-1-[(1*R*,3*S*,4*S*)-3-[5-(9,9-difluoro-7-{2-[(6*S*)-5-{(2*S*)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl]-5-azaspiro[2.4]hept-6-yl]-1*H*-imidazol-4-yl]-9*H*-fluoren-2-yl)-1*H*-benzimidazol-2-yl]-2-azabicyclo[2.2.1]heptane-2-carbonyl]-2-methylpropyl]carbamate


## lédipasvir

[(1*S*)-1-[(1*R*,3*S*,4*S*)-3-[5-(9,9-difluoro-7-{2-[(6*S*)-5-{(2*S*)-2-[(méthoxycarbonyl)amino]-3-méthylbutanoyl]-5-azaspiro[2.4]hept-6-yl]-1*H*-imidazol-4-yl]-9*H*-fluorén-2-yl)-1*H*-benzimidazol-2-yl]-2-azabicyclo[2.2.1]heptane-2-carbonyl]-2-méthylpropyl]carbamate de méthyle

## ledipasvir

[(1*S*)-1-[(1*R*,3*S*,4*S*)-3-[5-(9,9-difluoro-7-{2-[(6*S*)-5-{(2*S*)-2-[(metoxycarbonil)amino]-3-metilbutanoil]-5-azaespiro[2.4]hept-6-il]-1*H*-imidazol-4-yl]-9*H*-fluoren-2-il)-1*H*-benzimidazol-2-il]-2-azabicyclo[2.2.1]heptano-2-carbonil]-2-metilpropil]carbamato de metilo

C<sub>49</sub>H<sub>54</sub>F<sub>2</sub>N<sub>8</sub>O<sub>6</sub>



**lexanopadolum**


lexanopadol

*trans*-6'-fluoro-*N*-methyl-4-phenyl-4',9'-dihydro-3'*H*-spiro[cyclohexane-1,1'-pyrano[3,4-*b*]indol]-4-amine

lexanopadol

*trans*-6'-fluoro-*N*-méthyl-4-phényl-4',9'-dihydro-3'*H*-spiro[cyclohexane-1,1'-pyrano[3,4-*b*]indol]-4-amine

lexanopadol

*trans*-6'-fluoro-*N*-metil-4-fenil-4',9'-dihidro-3'*H*-espiro[ciclohexano-1,1'-pirano[3,4-*b*]indol]-4-aminaC<sub>23</sub>H<sub>25</sub>FN<sub>2</sub>O**liafensinum**


liafensine

6-[(4*S*)-2-methyl-4-(naphthalen-2-yl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine

liafensine

6-[(4*S*)-2-méthyl-4-(naphtalén-2-yl)-1,2,3,4-tétrahydroisoquinolin-7-yl]pyridazin-3-amine

liafensina




6-[(4*S*)-2-metil-4-(naftalen-2-il)-1,2,3,4-tetrahydroisoquinolin-7-il]piridazin-3-aminaC<sub>24</sub>H<sub>22</sub>N<sub>4</sub>**margetuximabum #**


margetuximab

immunoglobulin G1-kappa, anti-[*Homo sapiens* ERBB2 (epidermal growth factor receptor 2, HER-2, p185c-erbB2, NEU, EGFR2)], chimeric monoclonal antibody; gamma1 heavy chain (1-450) [*Mus musculus* VH (IGHV14-3\*02 - (IGHD)-IGHJ4\*01) [8.8.13] (1-120) - *Homo sapiens* IGHG1\*01 (CH1 K120>R (217) (121-218), hinge (219-233), CH2 L1.2>V (238), F7>L (246), R83>P (295), Y85.2>L (303) (234-343), CH3 P83>L (399) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfide with kappa light chain (1'-214') [*Mus musculus* V-KAPPA (IGKV6-17\*01 - IGKJ1\*01) [6.3.9] (1'-107') - *Homo sapiens* IGKC\*01 (108'-214')]; dimer (229-229":232-232")-bisdisulfide

|              |   |
|--------------|---|
| margétuximab | immunoglobuline G1-kappa, anti-[ <i>Homo sapiens</i> ERBB2 (récepteur 2 du facteur de croissance épidermique, HER-2, p185c-erbB2, NEU, EGFR2)], anticorps monoclonal chimérique; chaîne lourde gamma1 (1-450) [ <i>Mus musculus</i> VH (IGHV14-3*02 - (IGHD)-IGHJ4*01) [8.8.13] (1-120) - <i>Homo sapiens</i> IGHG1*01 (CH1 K120>R (217) (121-218), charnière (219-233), CH2 L1.2>V (238), F7>L (246), R83>P (295), Y85.2>L (303) (234-343), CH3 P83>L (399) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfure avec la chaîne légère kappa (1'-214') [ <i>Mus musculus</i> V-KAPPA (IGKV6-17*01 -IGKJ1*01) [6.3.9] (1'-107') - <i>Homo sapiens</i> IGKC*01 (108'-214')]; dimère (229-229":232-232")-bisdisulfure |
| margetuximab | immunoglobulina G1-kappa, anti-[ERBB2 de <i>Homo sapiens</i> (receptor 2 del factor de crecimiento epidérmico, HER-2, p185c-erbB2, NEU, EGFR2)], anticuerpo monoclonal quimérico; cadena pesada gamma1 (1-450) [ <i>Mus musculus</i> VH (IGHV14-3*02 - (IGHD)-IGHJ4*01) [8.8.13] (1-120) - <i>Homo sapiens</i> IGHG1*01 (CH1 K120>R (217) (121-218), bisagra (219-233), CH2 L1.2>V (238), F7>L (246), R83>P (295), Y85.2>L (303) (234-343), CH3 P83>L (399) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfuro con la cadena ligera kappa (1'-214') [ <i>Mus musculus</i> V-KAPPA (IGKV6-17*01 -IGKJ1*01) [6.3.9] (1'-107') - <i>Homo sapiens</i> IGKC*01 (108'-214')]; dímero (229-229":232-232")-bisdisulfuro   |
|              | Heavy chain / Chaîne lourde / Cadena pesada<br>QVQLQSQSGPE LVKPGASLKL SCTASGFFNIK DTYIHWVKQR PEQGLEWIGR 50<br>IYPTNGYTRY DPKFQDKATI TADTSSNTAY LQVSRRLTSED TAVYYCSRWG 100<br>GDGFYAMDYWG GQGASVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150<br>DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSTVTP VPSSSLGTQT 200<br>YICNVNHPKS NTKVDKRVPE KSCDKHTCP PCPAPELVGG PSVFLPPKP 250<br>KDTLMISRTPEVTCVVVDVSD HEDPEVKFNW YVDGVEVHNA KTKPPEEQYN 300<br>STLRVSVLT VHLQDNLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350<br>VYTLPPSRDE LTKNQVSLTLC LVKGFPYSDI AVEWESNGQP ENNYKTTPLV 400<br>LDSGDSFELY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPEGK 450  |
|              | Light chain / Chaîne légère / Cadena ligera<br>DIVMTQSHKF MSTSVGDRVS ITCKASQDVN TAVAWYQKQP GHSPKLLIYS 50<br>ASFRYTGVPD RFTGSRSGTD FTFTISSVQA EDLAVYYCQQ HTTPTPTFGG 100<br>GTRKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWVK 150<br>DNALQSGNSQ ESVTEDQSKD STYSLSSITL LSKADYEKHK VYACEVTHQG 200<br>LSSPVTKSFN RGEC 214  |
|              | Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro<br>Intra-H (C23-C104) 22-96 147-203 264-324 370-428<br>22"-96" 147"-203" 264"-324" 370"-428"<br>Intra-L (C23-C104) 23'-88" 134'-194"<br>23'"-88'" 134'"-194'"<br>Inter-H-L (h 5-CL 126) 223-214' 223"-214"<br>Inter-H-H (h 11, h 14) 229-229" 232-232"  |
|              | N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación<br>H CH2 N84.4:<br>300, 300"   |
| mavatrepum   |   |
| mavatrep     | 2-[2-(2-((1E)-2-(trifluoromethyl)phenyl)ethenyl)-1H-benzimidazol-5-yl)phenyl]propan-2-ol  |
| mavatrep     | 2-[2-(2-((1E)-2-(trifluorométhyl)phényl)éthényl)-1H-benzimidazol-5-yl)phényl]propan-2-ol  |
| mavatrep     | 2-[2-(2-((1E)-2-(trifluorometil)fenil]etenil)-1H-benzoimidazol-5-il)fenil]propan-2-ol   |



|                                     |  |
|-------------------------------------|--|
|                                     | $C_{25}H_{21}F_3N_2O$    |
| <b>methylsamidorphani chloridum</b> | (17 <i>R</i> )-3-carbamoyl-17-(cyclopropylmethyl)-4,14-dihydroxy-17-methyl-6-oxomorphinan-17-ium chloride  |
| methylsamidorphan chloride          |  |
| chlorure de méthylsamidorphan       | chlorure de (17 <i>R</i> )-3-carbamoyl-17-(cyclopropylméthyl)-4,14-dihydroxy-17-méthyl-6-oxomorphinanium   |
| cloruro de metilsamidorfano         | cloruro de (17 <i>R</i> )-3-carbamoil-17-(ciclopropilmetil)-4,14-dihidroxi-17-metil-6-oxomorfinanio  |
|                                     | $C_{22}H_{29}ClN_2O_4$   |
| <b>mirogabalinum</b>                | [(1 <i>R</i> ,5 <i>S</i> ,6 <i>S</i> )-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid   |
| mirogabalin                         |  |
| mirogabaline                        | acide [(1 <i>R</i> ,5 <i>S</i> ,6 <i>S</i> )-6-(aminométhyl)-3-éthylbicyclo[3.2.0]hept-3-én-6-yl]acétique  |
| mirogabalina                        | ácido 2-[(1 <i>R</i> ,5 <i>S</i> ,6 <i>S</i> )-6-(aminometil)-3-etilbicio[3.2.0]hept-3-en-6-il]acético   |
|                                     | $C_{12}H_{19}NO_2$    |
| <b>nebeterminum #</b>               |  |
| nebetermin                          | recombinant DNA derived L-methionyl-human bone morphogenetic protein 2 (BMP-2 or BMP-2A), produced in <i>Escherichia coli</i> (nonglycosylated)            |
| nébotermine                         | L-méthionyl-protéine 2 morphogénétique de l'os humaine (BMP-2 ou BMP-2A), produite par <i>Escherichia coli</i> (non glycosylée) à partir d'ADN recombinant |
| nebetermina                         | L-metionil-proteína 2 morfogenética humana de hueso (BMP-2 o BMP-2A), producida por <i>Escherichia coli</i> (no glicosilada) a partir de ADN recombinante  |



Monomer / Monomère / Monómero

QAKHKQRKRL KSSCKRHPLY VDFSDVGWND WIVAPPGYHA FYCHGECFPF 50  
 LADHLNSTNH AIVQTLVNSV NSKIPKACCV PTELSAISML YLDENEKVVL 100  
 KNYQDMVVEG CGCR 114

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro  
 14-79 14'-79' 43-111 43'-111' 47-113 47'-113' 78-78'

**nobiprostolanum**

nobiprostolan


propan-2-yl (5*E*)-7-[(1*R*,2*R*,3*R*,5*S*)-2-[2-(2-heptyl-1,3-dioxolan-2-yl)ethyl]-3,5-dihydroxycyclopentyl]hept-5-enoate

nobiprostolan

(5*E*)-7-[(1*R*,2*R*,3*R*,5*S*)-2-[2-(2-heptyl-1,3-dioxolan-2-yl)éthyl]-3,5-dihydroxycyclopentyl]hept-5-énoate de propan-2-yle

nobiprostolán

(5*E*)-7-[(1*R*,2*R*,3*R*,5*S*)-2-[2-(2-heptil-1,3-dioxolan-2-il)etil]-3,5-dihidroxiciclopentil]hept-5-enoato de propan-2-ilo

**ombitasvirum**

ombitasvir



dimethyl *N,N'*-{[(2*S*,5*S*)-1-(4-*tert*-butylphenyl)pyrrolidine-2,5-diyl]-bis-[[[(4,1-phenyleneazanediyl)carbonyl][(2*S*)-pyrrolidine-2,1-diyl]][(2*S*)-3-methyl-1-oxobutane-1,2-diyl]]}biscarbamate

ombitasvir

*N,N'*-{[(2*S*,5*S*)-1-(4-*tert*-butylphényl)pyrrolidine-2,5-diyl]-bis-[[[(4,1-phénylèneazanediyl)carbonyl][(2*S*)-pyrrolidine-2,1-diyl]][(2*S*)-3-méthyl-1-oxobutane-1,2-diyl]]}biscarbamate de diméthyle

ombitasvir

*N,N'*-{[(2*S*,5*S*)-1-(4-*terc*-butilfenil)pirrolideno-2,5-diil]-bis-[[[(4,1-fenilenoazanodiil)carbonil][(2*S*)-pirrolidina-2,1-diil]][(2*S*)-3-metil-1-oxobutano-1,2-diil]]}biscarbamato de dimetilo



**ontuxizumabum #**

ontuxizumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* CD248 (endosialin, tumor endothelial marker 1, TEM1), humanized/chimeric monoclonal antibody;

gamma1 heavy chain (1-454) [chimeric VH (*Homo sapiens*IGHV4-59\*04 (68.00%) -(IGHD)-IGHJ4\*01) [8.8.17] (1-124) -*Homo sapiens*IGHG1\*01 (CH1 (125-222), hinge (223-237), CH2 (238-347), CH3 S85.3>F (410) (348-452), CHS (453-454)) (125-454)], (227-215')-disulfide with kappa light chain (1'-215') [humanized V-KAPPA (*Homo sapiens*IGKV1-33\*01 (83.20%) -IGKJ1\*01) [6.3.10] (1'-108') -*Homo sapiens*IGKC\*01 (109'-215')]; dimer (233-233":236-236")-bisdisulfide

ontuxizumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* CD248 (endosialine, marqueur endothélial tumoral 1, TEM1)], anticorps monoclonal humanisé/chimérique;  
chaîne lourde gamma1 (1-454) [VH chimérique (*Homo sapiens*IGHV4-59\*04 (68.00%) -(IGHD)-IGHJ4\*01) [8.8.17] (1-124) -*Homo sapiens*IGHG1\*01 (CH1 (125-222), charnière (223-237), CH2 (238-347), CH3 S85.3>F (410) (348-452), CHS (453-454)) (125-454)], (227-215')-disulfure avec la chaîne légère kappa (1'-215') [V-KAPPA humanisé (*Homo sapiens*IGKV1-33\*01 (83.20%) -IGKJ1\*01) [6.3.10] (1'-108') -*Homo sapiens*IGKC\*01 (109'-215')]; dimère (233-233":236-236")-bisdisulfure

ontuxizumab

inmunoglobulina G1-kappa, anti-[CD248 de *Homo sapiens* (endosialina, marcador endotelial tumoral 1, TEM1)], anticuerpo monoclonal humanizado/quimérico;  
cadena pesada gamma1 (1-454) [VH quimérico (*Homo sapiens*IGHV4-59\*04 (68.00%) -(IGHD)-IGHJ4\*01) [8.8.17] (1-124) -*Homo sapiens*IGHG1\*01 (CH1 (125-222), bisagra (223-237), CH2 (238-347), CH3 S85.3>F (410) (348-452), CHS (453-454)) (125-454)], (227-215')-disulfuro con la cadena ligera kappa (1'-215') [V-KAPPA humanizada (*Homo sapiens*IGKV1-33\*01 (83.20%) -IGKJ1\*01) [6.3.10] (1'-108') -*Homo sapiens*IGKC\*01 (109'-215')]; dímero (233-233":236-236")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada  
QVQLQESGPG LVRPSQTLST TCTASGYTFT DYVIHWVKQP PGRGLEWIGY 50  
INPYDDDDTTY NQKFKGRVTM LVDTSSTNTAY LRLSSVTAED TAVYYCARRG 100  
NSYDGYFDYS MDYWGSGTPV TVSSASTKGP SVFPLAPSSK STSGGTAALG 150  
CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVTVTPSSSL 200  
GTQTYICNVN HKPSNTKVDK KVEPKSCDKT HTCPPCPAPE LLGGPSVFLF 250  
PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE VHNAKTKPRE 300  
EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKALPAPIE KTISKAKGQP 350  
REPQVYTLFP SRDELTKNQV SLTCLVKGFE PSDIAVEWES NGQPENNYKT 400  
TPPVLDSDGF FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL 450  
SPGK 454

Light chain / Chaîne légère / Cadena ligera  
DIQMTQSPSS LSASVGDRTV ITCRASQNVG TAVAWLQQTP GKAPKLLIYS 50  
ASNRYTGVPF RFSGSGSGTD YFTTISLQF EDIATYYCQQ YTNYPMYTFG 100  
QGTKVQIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNPF YPREAKVQWK 150  
VDNALQSGNS QESVTEQDSK DSTYSLSTL TLSKADYEK KKYACEVTHQ 200  
GLSSPVTKSF NRGEC 215

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 151-207 268-328 374-432  
22"-96" 151"-207" 268"-328" 374"-432"

Intra-L (C23-C104) 23'-88' 135'-195'  
23'''-88''' 135'''-195'''

Inter-H-L (h 5-CL 126) 227-215' 227"-215"

Inter-H-H (h 11, h 14) 233-233" 236-236"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:  
304, 304"

**oreptacogum alfa (activatum) #**  
oreptacog alfa (activated)

recombinant DNA derived human blood coagulation factor VIIa (two protein chains) analogue, produced in CHO cells (glycoform alfa): [10-L-glutamine(P>Q),32-L-glutamic acid(K>E),34-L-glutamic acid(A>E),36-L-glutamic acid(R>E),106-L-asparagine(T>N),253-L-asparagine(V>N)]activated human coagulation factor VII (proconvertine, SPCA)

## oreptacog alfa (activé)

analogue du facteur de coagulation sanguine VIIa (deux chaînes protéiques) humain, produit par des cellules ovariennes de hamster chinois (CHO) à partir d'ADN recombinant (glycoforme alfa) : [10-L-glutamine(P>Q),32-L-acide glutamique(K>E),34-L-acide glutamique(A>E),36-L-acide glutamique(R>E),106-L-asparagine(T>N),253-L-asparagine(V>N)]facteur de coagulation VII humain activé (proconvertine, SPCA)

## oreptacog alfa (activado)

análogo del factor VIIa de coagulación (dos cadenas proteicas) humano, producido por células ováricas de hamster chino (CHO) a partir de ADN recombinante (glicoforma alfa) : [10-L-glutamina(P>Q),32-L-ácido glutámico(K>E),34-L-ácido glutámico (A>E),36-L-ácido glutámico(R>E),106-L-asparagina(T>N),253-L-asparagina(V>N)]factor de coagulación VII humano activado (proconvertina, SPCA)

## Light chain / Chaîne légère / Cadenena ligera

ANAFLEELRQ GSLERECKEE QCSFEEAREI FEDEEETKLF WISYSDGDQC 50  
ASSPCQNGGS CKDQLQSYIC FCLPAFEGRN CETHKDDQLI CVNENGGEQ 100  
YCSDHNGTKR SCRCHEGYSL LADGVSCSTPT VEYPCGKIPI LEKRNASKFP 150  
GR 152


## Heavy chain / Chaîne lourde / Cadena pesada

IVGGKVCVP KGECPWQVLL LVNGAQLCGG TLINTIIVVVS AAHCFDKIKN 200  
WRNLIIVLGE HDLSEHDGDE QSRRAQVVI PSTYVPGTTN HDIALLRLHQ 250  
PVNLTDHVVP LCLPERTFSE RTLAFVRFSL VSCWGQLLDR GATALELMVL 300  
NVPRMTQDC LQOSRKVGDS FNTIETMFCA GYSDGSKDSC KGDSGGPHAT 350  
HYRGTWYLTG IVSWGQGCAT VGHFVGTVRV SQYIEWLQKL MRSEPRPGVL 400  
LRAPFF 406

## Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

17-22 50-61 55-70 72-81 91-102 98-112  
114-127 135-262 159-164 178-194 310-329 340-368

## Modified residues / Résidus modifiés / Restos modificados



## Glycosylation sites (S or N) / Sites de glycosylation (S ou N) / Posiciones de glicosilación (S o N)

Ser-52 Ser-60 Asn-106 Asn-145 Asn-253 Asn-322

**paclitaxelum trevatidum**  
paclitaxel trevatide

short modified fragment of human amyloid beta A4 protein covalently linked to three molecules of paclitaxel through succinyl linkers:  $N^{2,1}, N^{6,10}, N^{6,15}$ -tris{4-[(1S,2R)-1-benzamido-3-[(2S,5R,7S,10R,13S)-10,12-bis(acetyloxy)-2-benzoyl-1,7-dihydroxy-9-oxo-5,20-epoxytax-11-en-13-yl]oxy]-3-oxo-1-phenylpropan-2-yl]oxy]-4-oxobutanoyl} ([318-L-threonine(P>I<sup>1</sup>),324-L-serine(C>S<sup>7</sup>),325-L-arginine(G>R<sup>8</sup>),327-L-lysine(N>K<sup>10</sup>),332-L-lysine(N>K<sup>15</sup>)] human amyloid beta A4 protein precursor-(318-336)-peptide)

## paclitaxel trévatide


fragment court et modifié de la protéine bêta A4 amyloïde humaine lié de façon covalente à trois molécules de paclitaxel par autant de succinyles :  $N^{2,1}, N^{6,10}, N^{6,15}$ -tris{4-[(1S,2R)-1-benzamido-3-[(2S,5R,7S,10R,13S)-10,12-bis(acétyloxy)-2-benzoyl-1,7-dihydroxy-9-oxo-5,20-époxytax-11-en-13-yl]oxy]-3-oxo-1-phénylpropan-2-yl]oxy]-4-oxobutanoyl} ([318-L-thréonine(P>I<sup>1</sup>),324-L-sérine(C>S<sup>7</sup>),325-L-arginine(G>R<sup>8</sup>),327-L-lysine(N>K<sup>10</sup>),332-L-lysine(N>K<sup>15</sup>)] précurseur de la protéine amyloïde bêta A4 humaine-(318-336)-peptide)

paclitaxel trevatida

fragmento corto y modificado de la proteína beta A4 amiloide humana unido covalentemente a tres moléculas de paclitaxel mediante succinilos :  
 $N^{2,1}, N^{6,10}, N^{6,15}$ -tris{4-[(1*S*,2*R*)-1-benzamido-3-[[[(2*S*,5*R*,7*S*,10*R*,13*S*)-10,12-bis(acetiloxi)-2-benzoil-1,7-dihidroxi-9-oxo-5,20-epoxitax-11-en-13-il]oxi]-3-oxo-1-fenilpropan-2-il)oxi]-4-oxobutanoil} ([318-L-treonina(P>I<sup>1</sup>),324-L-serina(C>S<sup>7</sup>),325-L-arginina(G>R<sup>8</sup>),327-L-lisina(N>K<sup>10</sup>),332-L-lisina(N>K<sup>15</sup>)] precursor de la proteína amiloide beta A4 humana-(318-336)-péptido  
 $C_{257}H_{308}N_{32}O_{79}$

Peptide / Peptide / Péptide  
 $\text{TFFYGGSRGK RNNFKTEEY}$  19

Modified residues / Résidus modifiés / Restos modificados



**palbociclibum**  
 palbociclib


6-acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]pyrido[2,3-*d*]pyrimidin-7(8*H*)-one

palbociclib

6-acétyl-8-cyclopentyl-5-méthyl-2-[[5-(pipérazin-1-yl)pyridin-2-yl]amino]pyrido[2,3-*d*]pyrimidin-7(8*H*)-one

palbociclib

6-acetil-8-ciclopentil-5-metil-2-[[5-(piperazin-1-il)piridin-2-il]amino]pirido[2,3-*d*]pirimidin-7(8*H*)-ona

 $C_{24}H_{29}N_7O_2$ 


**panulisibum**  
 panulisib



2-(5-((2*EZ*)-8-[6-amino-5-(trifluoromethyl)pyridin-3-yl]-2-(cyanoimino)-3-methyl-2,3-dihydro-1*H*-imidazo[4,5-*c*]quinolin-1-yl]pyridin-2-yl)-2-methylpropanenitrile

panulisib

2-(5-((2*EZ*)-8-[6-amino-5-(trifluorométhy)pyridin-3-yl]-2-(cyanoimino)-3-méthyl-2,3-dihydro-1*H*-imidazo[4,5-*c*]quinoléin-1-yl]pyridin-2-yl)-2-méthylpropanenitrile

panulisib

2-(5-((2*EZ*)-8-[6-amino-5-(trifluorometil)pyridin-3-il]-2-(cianoimino)-3-metil-2,3-dihidro-1*H*-imidazo[4,5-*c*]quinolin-1-il]piridin-2-il)-2-metilpropanonitrilo



**patisiranum**  
patisiran


small interfering RNA (siRNA);  
RNA duplex of guanylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-adenylyl-(3'→5')-adenylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-adenylyl-(3'→5')-adenylyl-(3'→5')-guanylyl-(3'→5')-adenylyl-(3'→5')-guanylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-adenylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-adenylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-thymidylyl-(3'→5')-thymidine with thymidylyl-(5'→3')-thymidylyl-(5'→3')-cytidylyl-(5'→3')-adenylyl-(5'→3')-2'-O-methyluridylyl-(5'→3')-uridylyl-(5'→3')-guanylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-uridylyl-(5'→3')-cytidylyl-(5'→3')-uridylyl-(5'→3')-cytidylyl-(5'→3')-adenylyl-(5'→3')-2'-O-methyluridylyl-(5'→3')-adenylyl-(5'→3')-adenylyl-(5'→3')-guanylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-adenosine

patisiran

petit ARN interférant (siRNA);  
duplex ARN du brin guanylyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')-adénylyl-(3'→5')-adénylyl-(3'→5')-2'-O-méthylcytidylyl-(3'→5')-2'-O-méthylcytidylyl-(3'→5')-adénylyl-(3'→5')-adénylyl-(3'→5')-guanylyl-(3'→5')-adénylyl-(3'→5')-guanylyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')-adénylyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')-2'-O-méthylcytidylyl-(3'→5')-2'-O-méthylcytidylyl-(3'→5')-adénylyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')-thymidylyl-(3'→5')-thymidine avec le brin anti-sens thymidylyl-(5'→3')-thymidylyl-(5'→3')-cytidylyl-(5'→3')-adénylyl-(5'→3')-2'-O-méthyluridylyl-(5'→3')-uridylyl-(5'→3')-guanylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-uridylyl-(5'→3')-cytidylyl-(5'→3')-uridylyl-(5'→3')-adénylyl-(5'→3')-2'-O-méthyluridylyl-(5'→3')-adénylyl-(5'→3')-adénylyl-(5'→3')-guanylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-adénosine


patisirán

ARN interferente pequeño (siRNA);  
ARN dúplex de la cadena guanilil-(3'→5')-2'-O-metiluridilil-(3'→5')-adenilil-(3'→5')-adenilil-(3'→5')-2'-O-metilcitidilil-(3'→5')-2'-O-metilcitidilil-(3'→5')-adenilil-(3'→5')-adenilil-(3'→5')-guanilil-(3'→5')-adenilil-(3'→5')-guanilil-(3'→5')-2'-O-metiluridilil-(3'→5')-adenilil-(3'→5')-2'-O-metiluridilil-(3'→5')-2'-O-metiluridilil-(3'→5')-2'-O-metilcitidilil-(3'→5')-2'-O-metilcitidilil-(3'→5')-adenilil-(3'→5')-2'-O-metiluridilil-(3'→5')-timidilil-(3'→5')-timidina con la cadena antisentido timidilil-(5'→3')-timidilil-(5'→3')-citidilil-(5'→3')-adenilil-(5'→3')-2'-O-metiluridilil-(5'→3')-uridilil-(5'→3')-guanilil-(5'→3')-guanilil-(5'→3')-uridilil-(5'→3')-uridilil-(5'→3')-citidilil-(5'→3')-uridilil-(5'→3')-citidilil-(5'→3')-adenilil-(5'→3')-2'-O-metiluridilil-(5'→3')-adenilil-(5'→3')-adenilil-(5'→3')-guanilil-(5'→3')-guanilil-(5'→3')-uridilil-(5'→3')-adenosina



(3'-5')G-U-A-A-C-C-A-A-G-A-G-U-A-U-U-C-C-A-U-dT-dT  
(5'-3')dT-dT-C-A-U-U-G-G-U-U-C-U-C-A-U-A-A-G-G-U-A

Modified nucleosides (C and U) / Nucléosides modifiés (C et U) / Nucleósidos modificados (C y U)



**pegbovigrastimum #**  
pegbovigrastim

recombinant DNA derived bovine granulocyte colony-stimulating factor (G-CSF) analogue, produced in *Escherichia coli* (nonglycosylated), covalently bonded to methoxy polyethylene glycol:

L-methionyl-[133-{4-(1-{{[ω-methoxypoly(oxyethylene)]carbonyl}amino}ethoxy)imino}ethyl)-L-phenylalanine(T>E)]]bovine granulocyte colony-stimulating factor (G-CSF)

pegbovigrastim


analogue du facteur de stimulation de colonies de granulocytes bovin, produit par *Escherichia coli* à partir d'ADN recombinant (non glycosylé), auquel est liée de façon covalente une chaîne méthoxypolyéthylèneglycol :

L-méthionyl-[133-{4-(1-{{[ω-méthoxypoly(oxyéthylène)]carbonyl}amino}éthoxy)imino}éthyl)-L-phénylalanine(T>E)]]facteur de stimulation des colonies de granulocytes (G-CSF) bovin

pegbovigrastim

análogo del factor bovino estimulante de colonias de granulocitos, producido por *Escherichia coli* a partir de ADN recombinante (no glicosilado), al cual se une covalentemente una cadena metoxipolietilenglicol :

L-metionil-[133-{4-(1-{{[ω-metoxipoli(oxiétileno)]carbonil}amino}etoxi}imino}etil)-L-fenilalanina(T>E)]]factor estimulante de colonias de granulocitos (G-CSF) bovino




Sequence / Séquence / Secuencia

|            |            |            |            |            |     |
|------------|------------|------------|------------|------------|-----|
| TPLGPARSLP | QSFLLKCLEQ | VRKIQADGAE | LQERLCAAHK | LCHPEELMLL | 50  |
| RHSLGIPQAP | LSSCSSQSLQ | LTSCINQLHG | GLFLYQGLLQ | ALAGISPELA | 100 |
| PTLDTLQLDV | TDFATNIWLQ | MEDLGAAPAV | QFFQGAMPTF | TSAFQRRAGG | 150 |
| VLVASQLHRF | LELAYRGLRY | LAEP       |            |            | 174 |

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro  
36-42 64-74

Modified residue / Résidu modifié / Resto modificado



**pegteograstimum #**  
pegteograstim

recombinant DNA derived human granulocyte colony-stimulating factor (G-CSF) analogue, produced in *Escherichia coli* (nonglycosylated), covalently bonded to methoxy polyethylene glycol:  
 endo-139a-S-((3*RS*)-1-[3-({3-[ω-methoxypoly(oxyethylene)]propyl}amino)-3-oxopropyl]-2,5-dioxopyrrolidin-3-yl)-L-cysteine (->C<sup>137</sup>)-des-(37-39)-[1-L-methionine(A>M),18-L-serine(C>S)]human granulocyte colony stimulating factor (G-CSF, pluripoietin)

## pegtéograstim

analogue du facteur humain de stimulation de colonies de granulocytes, produit par *Escherichia coli* à partir d'ADN recombinant (non glycosylé), auquel est lié de façon covalente une chaîne méthoxypolyéthylèneglycol :  
 endo-139a-S-((3*RS*)-1-[3-({3-[ω-méthoxypoly(oxyéthylène)]propyl}amino)-3-oxopropyl]-2,5-dioxopyrrolidin-3-yl)-L-cystéine(->C<sup>137</sup>)-dès-(37-39)-[1-L-méthionine(A>M),18-L-sérine(C>S)]facteur humain de stimulation de colonies de granulocytes (G-CSF, pluripoétine)

## pegteograstim

análogo del factor humano estimulante de colonias de granulocitos, producido por *Escherichia coli* a partir de ADN recombinante (no glicosilado), al que se une covalentemente una cadena metoxipolietilenglicol:  
 endo-139a-S-((3*RS*)-1-[3-({3-[ω-metoxipoli(oxietileno)]propil}amino)-3-oxopropil]-2,5-dioxopirrolidin-3-il)-L-cisteina(->C<sup>137</sup>)-des-(37-39)-[1-L-metionina(A>M),18-L-serina(C>S)]factor humano estimulante de colonias de granulocitos (G-CSF, pluripoyetina)


$C_{859}H_{1360}N_{226}O_{249}S_9 \cdot [C_2H_4O]_n$

## Sequence / Séquence / Secuencia

MTPLGPASSL PQSFLKLSLE QVRKIQGDGA ALQEKLCATY KLCHPEELVL 50  
 LGHSLGIPWA PLSSCPSQAL QLAGCLSQLH SGLFLYQGLL QALEGISPEL 100  
 GPTLDTLQLD VADFATTIWQ QMEELGMAPA LQPTQGQAMP AFASAFQRRRA 150  
 GGVLVASHLQ SFLEVSRYRL RHLAQP 176

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro  
 37-43 65-75

## Modified residue / Résidu modifié / Resto modificado

**pevonedistatum**  
pevonedistat

[(1*S*,2*S*,4*R*)-4-(4-[[[(1*S*)-2,3-dihydro-1*H*-inden-1-yl]amino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl)-2-hydroxycyclopentyl]methyl sulfamate


## pévonedistat

sulfamate de [(1*S*,2*S*,4*R*)-4-(4-[[[(1*S*)-2,3-dihydro-1*H*-indén-1-yl]amino]-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl)-2-hydroxycyclopentyl]méthyle

## pevonedistat

sulfamato de (1*S*,2*S*,4*R*)-4-(4-[[[(1*S*)-2,3-dihidro-1*H*-inden-1-il]amino]-7*H*-pirrolo[2,3-*d*]pirimidin-7-il)-2-hidroxiciclopentil]metilo



$C_{21}H_{25}N_5O_4S$ 

**ralimetinibum**  
ralimetinib


5-[2-*tert*-butyl-5-(4-fluorophenyl)-1*H*-imidazol-4-yl]-  
3-(2,2-dimethylpropyl)-3*H*-imidazo[4,5-*b*]pyridin-2-amine

ralimétinib

5-[2-*tert*-butyl-5-(4-fluorophényl)-1*H*-imidazol-4-yl]-  
3-(2,2-diméthylpropyl)-3*H*-imidazo[4,5-*b*]pyridin-2-amine

ralimetinib

5-[2-*terc*-butil-5-(4-fluorofenil)-1*H*-imidazol-4-il]-3-(2,2-dimetilpropil)-  
3*H*-imidazo[4,5-*b*]piridin-2-amina

 $C_{24}H_{29}FN_6$ 

**remeglurantum**  
remeglurant


(6-bromopyrazolo[1,5-*a*]pyrimidin-2-yl)[(1*R*)-1-methyl-  
3,4-dihydroisoquinolin-2(1*H*)-yl]methanone

remégglurant

(6-bromopyrazolo[1,5-*a*]pyrimidin-2-yl)[(1*R*)-1-méthyl-  
3,4-dihydroisoquinoléin-2(1*H*)-yl]méthanone

remeglurant

(6-bromopirazolo[1,5-*a*]pirimidin-2-il)[(1*R*)-1-metil-  
3,4-dihidroisoquinolin-2(1*H*)-il]metanona

 $C_{17}H_{15}BrN_4O$ 

**ricolinostatum**  
ricolinostat



2-(diphenylamino)-*N*-[7-(hydroxyamino)-7-oxoheptyl]pyrimidine-  
5-carboxamide

ricolinostat

2-(diphénylamino)-*N*-[7-(hydroxyamino)-7-oxoheptyl]pyrimidine-  
5-carboxamide

ricolinostat

2-(difenilamino)-*N*-[7-(hidroxiamino)-7-oxoheptil]pirimidina-  
5-carboxamida

**rimegepantum**

rimegepant



(5*S*,6*S*,9*R*)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5*H*-cyclohepta[*b*]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1*H*-imidazo[4,5-*b*]pyridin-1-yl)piperidine-1-carboxylate

rimégépant

4-(2-oxo-2,3-dihydro-1*H*-imidazo[4,5-*b*]pyridin-1-yl)pipéridine-1-carboxylate de (5*S*,6*S*,9*R*)-5-amino-6-(2,3-difluorophényl)-6,7,8,9-tétrahydro-5*H*-cyclohepta[*b*]pyridin-9-yle

rimegepant

4-(2-oxo-2,3-dihydro-1*H*-imidazo[4,5-*b*]pyridin-1-il)piperidina-1-carboxilato de (5*S*,6*S*,9*R*)-5-amino-6-(2,3-difluorofenil)-6,7,8,9-tetrahydro-5*H*-ciclohepta[*b*]piridin-9-ilo

**ripasudilum**

ripasudil



4-fluoro-5-[[[(2*S*)-2-methyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline

ripasudil

4-fluoro-5-[[[(2*S*)-2-méthyl-1,4-diazépan-1-yl]sulfonyl]isoquinoléine

ripasudil

4-fluoro-5-[[[(2*S*)-2-metil-1,4-diazepan-1-il]sulfonyl]isoquinolina

**riviciclibum**

riviciclib



2-(2-chlorophenyl)-5,7-dihydroxy-8-[(2*R*,3*S*)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]-4*H*-1-benzopyran-4-one

riviciclib

2-(2-chlorophényl)-5,7-dihydroxy-8-[(2*R*,3*S*)-2-(hydroxyméthyl)-1-méthylpyrrolidin-3-yl]-4*H*-1-benzopyran-4-one

riviciclib

2-(2-clorofenil)-5,7-dihidroxi-8-[(2*R*,3*S*)-2-(hidroximetil)-1-metilpirrolidin-3-il]-4*H*-1-benzopiran-4-ona



**rivipanselum**  
rivipansel



(2S)-3-cyclohexyl-2-[[[(1R,2R,3S,5R)-2-[(6-deoxy- $\alpha$ -L-galactopyranosyl)oxy]-3-(2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-carboxamido)-5-[13-[[[3,6,8-trisulfonatophthalene-1-yl]amino]-6,13-dioxo-2,5-diaza-8,11-dioxatridecanoyl]cyclohexyl]{2-O-benzoyl- $\beta$ -D-galactopyranoside-3-O-yl)]propanoic acid

rivipansel

acide (2S)-3-cyclohexyl-2-(((1R,2R,3S,5R)-2-[[6-déoxy- $\alpha$ -L-galactopyranosyl)oxy]-3-(2,6-dioxo-1,2,3,6-tétrahydropyrimidin-4-carboxamido)-5-[13-[[3,6,8-trisulfonatonaphthalèn-1-yl)amino]-6,13-dioxo-2,5-diaza-8,11-dioxatridécanoyl]cyclohexyl]{2-O-benzoyl- $\beta$ -D-galactopyranosid-3-O-yl})propanoïque

rivipansel

ácido (2*S*)-3-ciclohexil-2-([(1*R*,2*R*,3*S*,5*R*)-2-[(6-desoxi- $\alpha$ -L-galactopiranosil)oxil]-3-(2,6-dioxo-1,2,3,6-tetrahidropirimidin-4-carboxamido)-5-[13-[(3,6,8-trisulfonatonaftalen-1-il)amino]-6,13-dioxo-2,5-diaza-8,11-dioxatridecanoil]ciclohexil] [2-*O*-benzoi- $\beta$ -D-galactopiranosid-3-*O*il]propanoico



**roniciclibum**


roniciclib

cyclopropyl(4-{[4-{[(2*R*,3*R*)-3-hydroxybutan-2-yl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)imino-λ<sup>5</sup>-sulfanone

roniciclib

cyclopropyl(4-{[4-{[(2*R*,3*R*)-3-hydroxybutan-2-yl]oxy}-5-(trifluorométhyl)pyrimidin-2-yl]amino}phényl)imino-λ<sup>5</sup>-sulfanone

roniciclib

ciclopropil(4-{[4-{[(2*R*,3*R*)-3-hidroxibutan-2-il]oxi}-5-(trifluorometil)pirimidin-2-il]amino}fenil)imino-λ<sup>5</sup>-sulfanonaC<sub>18</sub>H<sub>21</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub>S**ropeginterferonum alfa-2b #**

ropeginterferon alfa-2b

recombinant DNA derived human interferon alfa-2b with an added pegylated proline at its *N*-terminal, produced in *Escherichia coli* (nonglycosylated):{1-[(3*RS*)-3,7-bis{[(ω-methoxypoly(oxyethylene)carbonyl]amino)heptyl]-L-prolyl}human interferon alpha-2B

ropéginterféron alfa-2b

interféron alfa-2b humain auquel une proline pégylée a été rajoutée du côté *N*-terminal, produit par *Escherichia coli* (non glycosylé) à partir d'ADN recombinant :{1-[(3*RS*)-3,7-bis{[(ω-méthoxypoly(oxyéthylène)carbonyl]amino)heptyl]-L-prolyl}interféron alpha-2B humain

ropeginterferon alfa-2b

interferón alfa-2b humano con una prolina pegilada unida al extremo *N*-terminal, producido por *Escherichia coli* (no glicosilado) a partir de ADN recombinante :{1-[(3*RS*)-3,7-bis{[(ω-metoxipoli(oxietilen)carbonil]amino)heptil]-L-prolil}interferón alfa-2B humanoC<sub>876</sub>H<sub>1376</sub>N<sub>232</sub>O<sub>260</sub>S<sub>9</sub>[C<sub>2</sub>H<sub>4</sub>O]<sub>2n</sub>

Sequence / Séquence / Secuencia


|            |            |            |            |            |     |   |
|------------|------------|------------|------------|------------|-----|---|
|            |            |            |            |            | P   | 0 |
| CDLPQTHSLG | SRRTLMLLAQ | MRRISLFSL  | KDRHDFGFPQ | EEFGNQFQKA | 50  |   |
| ETIPVLHEMI | QQIFNLFSTK | DSSAAWDEL  | LKKFYTELYQ | QLNDLEACVI | 100 |   |
| QGVGVTEPL  | MKEDSILAVR | KYFQRITLYL | KEKYSPPCAW | EVVRAEIMRS | 150 |   |
| FSLSTNLQES | LRSKE      |            |            |            | 165 |   |

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro  
1-98 29-138

Modified residue / Résidu modifié / Resto modificado

P

1-[(mPEG)2link]Prolyl



**sacubitrilum**


sacubitril

4-[[[(2*S*,4*R*)-1-([1,1'-biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl]amino]-4-oxobutanoic acid

sacubitril

acide 4-[[[(2*S*,4*R*)-1-([1,1'-biphényl]-4-yl)-5-éthoxy-4-méthyl-5-oxopentan-2-yl]amino]-4-oxobutanoïque

sacubitrilo

ácido 4-[[[(2*S*,4*R*)-1-([1,1'-bifenil]-4-il)-5-etoxi-4-metil-5-oxopentan-2-il]amino]-4-oxobutanoicoC<sub>24</sub>H<sub>29</sub>NO<sub>5</sub>**sarecyclinum**


sarecycline

(4*S*,4*aS*,5*aR*,12*aS*)-4-(diméthylamino)-3,10,12,12*a*-tétrahydroxy-7-[[méthoxy(méthyl)amino]méthyl]-1,11-dioxo-1,4,4*a*,5,5*a*,6,11,12*a*-octahydrotétracène-2-carboxamide

sarécycline

(4*S*,4*aS*,5*aR*,12*aS*)-4-(diméthylamino)-3,10,12,12*a*-tétrahydroxy-7-[[méthoxy(méthyl)amino]méthyl]-1,11-dioxo-1,4,4*a*,5,5*a*,6,11,12*a*-octahydrotétracène-2-carboxamide

sareciclina

(4*S*,4*aS*,5*aR*,12*aS*)-4-(dimetilamino)-3,10,12,12*a*-tetrahidroxi-7-[[metoxi(metil)amino]metil]-1,11-dioxo-1,4,4*a*,5,5*a*,6,11,12*a*-octahidrotetraceno-2-carboxamidaC<sub>24</sub>H<sub>29</sub>N<sub>3</sub>O<sub>8</sub>**sarsageninum**

sarsagenin


(25*S*)-5β-spirostan-3β-ol

sarsagénine

(25*S*)-5β-spirostan-3β-ol

sarsagenina

(25*S*)-5β-espirostan-3β-ol

$C_{27}H_{44}O_3$ **sisapronilum**


sisapronil

5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(1*RS*)-2,2-difluoro-1-(trifluoromethyl)cyclopropyl]-1*H*-pyrazole-3-carbonitrile

sisapronil

5-amino-1-[2,6-dichloro-4-(trifluorométhyl)phényl]-4-[(1*RS*)-2,2-difluoro-1-(trifluorométhyl)cyclopropyl]-1*H*-pyrazole-3-carbonitrile

sisapronilo

5-amino-1-[2,6-dichloro-4-(trifluorometil)fenil]-4-[(1*RS*)-2,2-difluoro-1-(trifluorometil)ciclopropil]-1*H*-pirazol-3-carbonitrilo $C_{15}H_6Cl_2F_8N_4$ **smilageninum**


smilagenin

(25*R*)-5β-spirostan-3β-ol

smilagénine

(25*R*)-5β-spirostan-3β-ol

esmilagenina

(25*R*)-5β-espirostan-3β-ol $C_{27}H_{44}O_3$ **tanurmotidum**

tanurmotide

human lymphocyte antigen 6K-(101-111)-peptide

tanurmotide

antigène 6K lymphocytaire humain-(101-111)-peptide

tanurmotida

antígeno 6K linfocitario humano-(101-111)-péptido

 $C_{51}H_{80}N_{14}O_{15}S$ Sequence / Séquence / Secuencia  
RYCNLEGPPI 10

**tarextumabum #**

tarextumab

immunoglobulin G2-kappa, anti-[*Homo sapiens* NOTCH2 and NOTCH3], *Homo sapiens* monoclonal antibody;  
gamma2 heavy chain (1-441) [*Homo sapiens* VH (IGHV3-66\*01 (93.90%) -(IGHD)-IGHJ6\*01 T123>L (110)) [8.8.8] (1-115) -IGHG2\*01 (CH1 (116-213), hinge (214-225), CH2 (226-334), CH3 (335-439), CHS (440-441)) (116-441)], (129-215')-disulfide with kappa light chain (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20\*02 (94.40%) -IGKJ1\*01) [7.3.9] (1'-108') -IGKC\*01 (109'-215')]; dimer (217-217'':218-218'':221-221'':224-224'')-tetrakisdisulfide

tarextumab

immunoglobuline G2-kappa, anti-[*Homo sapiens* NOTCH2 et NOTCH3], *Homo sapiens* anticorps monoclonal;  
chaîne lourde gamma2 (1-441) [*Homo sapiens* (IGHV3-66\*01 (93.90%) -(IGHD)-IGHJ6\*01 T123>L (110)) [8.8.8] (1-115) -IGHG2\*01 (CH1 (116-213), charnière (214-225), CH2 (226-334), CH3 (335-439), CHS (440-441)) (116-441)], (129-215')-disulfure avec la chaîne légère kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20\*02 (94.40%) -IGKJ1\*01) [7.3.9] (1'-108') -IGKC\*01 (109'-215')]; dimère (217-217'':218-218'':221-221'':224-224'')-tétrakisdisulfure

tarextumab

immunoglobulina G2-kappa, anti-[NOTCH2 y NOTCH3 de *Homo sapiens*], anticuerpo monoclonal de *Homo sapiens*;  
cadena pesada gamma2 (1-441) [*Homo sapiens* (IGHV3-66\*01 (93.90%) -(IGHD)-IGHJ6\*01 T123>L (110)) [8.8.8] (1-115) -IGHG2\*01 (CH1 (116-213), bisagra (214-225), CH2 (226-334), CH3 (335-439), CHS (440-441)) (116-441)], (129-215')-disulfuro con la cadena ligera kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20\*02 (94.40%) -IGKJ1\*01) [7.3.9] (1'-108') -IGKC\*01 (109'-215')]; dímero (217-217'':218-218'':221-221'':224-224'')-tetrakisdisulfuro

## Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFTFS SSGMSWVRQA PGKGLEWVSV 50
IASVSGSNTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARSI 100
FYTTWGQGTLL VTVSSASTKG PSVFPLAPCS RSTSESTAAL GCLVKDYFFE 150
PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVTVFPSSN FGTQYTYTCNV 200
DHPKPSNTKVD KTVKRCCKVE CPPCPAPPVA GPSVFLFPPK PKDTLMISRT 250
PEVTCVVVDV SHEDFEVQFN WYVDGVEVHN AKTKPREEQF NSTFRVVSVL 300
TVVHQDWLNG KEYCKVSNK GLPAPIEKTI SKTKGQPREP QVYTLFPSSRE 350
EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTPP MLDSGDSFFL 400
YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG K 441
```

## Light chain / Chaîne légère / Cadena ligera

```
DIVLTQSPAT LSLSPGERAT LSCRASQSVR SNYLAWYQQK PGQAPRLLIY 50
GASSRATGVP ARFSGSGSGT DFTLTISLSE PEDFAVYYCQ QYSNFPITFG 100
QGRTKVEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYLSSTL TSKADYEKH KVYACEVTHQ 200
GLSPVTKSF NRGEK 215
```

## Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 142-198 255-315 361-419  
22"-96" 142"-198" 255"-315" 361"-419"  
Intra-L (C23-C104) 23'-89' 135'-195'  
23'''-89''' 135'''-195'''  
Inter-H-L (CH1 10-CL 126) 129-215' 129"-215"  
Inter-H-H (h 4, h 5, h 8, h 11) 217-217" 218-218" 221-221" 224-224"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación  
H CH2 N84.4:  
291, 291"

**taselisibum**

taselisib


2-methyl-2-(4-{2-[3-methyl-1-(propan-2-yl)-1*H*-1,2,4-triazol-5-yl]-5,6-dihydroimidazo[1,2-*d*][1,4]benzoxazepin-9-yl]-1*H*-pyrazol-1-yl)propanamide

tasélisib

2-méthyl-2-(4-{2-[3-méthyl-1-(propan-2-yl)-1*H*-1,2,4-triazol-5-yl]-5,6-dihydroimidazo[1,2-*d*][1,4]benzoxazépin-9-yl]-1*H*-pyrazol-1-yl)propanamide

taselisib

2-metil-2-(4-{2-[3-metil-1-(propan-2-il)-1*H*-1,2,4-triazol-5-yl]-5,6-dihidroimidazo[1,2-*d*][1,4]benzoxazepin-9-il]-1*H*-pirazol-1-il)propanamida

C<sub>24</sub>H<sub>28</sub>N<sub>8</sub>O<sub>2</sub>**technetii (<sup>99m</sup>Tc) trofolastati chloridum**  
technetium (<sup>99m</sup>Tc) trofolastat chloride


(OC-6-33)-tricarbonyl{(2*S*)-2-[[{[(1*S*)-1-carboxy-4-[[[(1*S*)-1-carboxy-5-(bis[1-(2-[[bis(carboxymethyl)]amino)-2-oxoethyl]-1*H*-imidazol-2-yl-κ*N*<sup>3</sup>]methyl]amino-κ*N*)pentyl]amino]-4-oxobutyl]carbonyl]amino)pentanedioic acid]}(<sup>99m</sup>Tc)technetium chloride

chlorure de technétium (<sup>99m</sup>Tc) trofolastat

chlorure de (<sup>99m</sup>Tc)technétium acide (OC-6-33)-tricarbonyl{(2*S*)-2-[[{[(1*S*)-1-carboxy-4-[[[(1*S*)-1-carboxy-5-(bis[1-(2-[[bis(carboxyméthyl)]amino)-2-oxoéthyl]-1*H*-imidazol-2-yl-κ*N*<sup>3</sup>]méthyl]amino-κ*N*)pentyl]amino]-4-oxobutyl]carbonyl]amino)pentanedioïque]}

cloruro de tecnecio (<sup>99m</sup>Tc) trofolastat

cloruro de ácido (OC-6-33)-tricarbonil{(2*S*)-2-[[{[(1*S*)-1-carboxi-4-[[[(1*S*)-1-carboxi-5-(bis[1-(2-[[bis(carboximetil)]amino)-2-oxoetil]-1*H*-imidazol-2-il-κ*N*<sup>3</sup>]metil]amino-κ*N*)pentil]amino]-4-oxobutil]carbamoil]amino)pentanedioico]}(<sup>99m</sup>Tc)tecnecio

C<sub>40</sub>H<sub>50</sub>ClN<sub>10</sub>O<sub>23</sub>Tc



|  |   |
|--|---|
| <b>topsalysinum #</b><br>topsalysin  | recombinant DNA derived proaerolysin, pore-forming protein, from <i>Aeromonas hydrophila</i> , with the furin site substituted with a prostate specific antigen (PSA), fusion protein with 6 histidines, produced in <i>Escherichia coli</i> (nonglycosylated):<br>[427-L-histidine(K>H),428-L-serine(V>S),429-L-serine(R>S),430-L-lysine(R>K),431-L-leucine(A>L),432-L-glutamine(R>Q)]proaerolysin <i>Aeromonas hydrophila</i> fusion protein with hexa-L-histidine  |
| topsalysine  | proaérolysine, protéine formant des pores, d' <i>Aeromonas hydrophila</i> dont le site furine est substitué par un antigène prostatique spécifique, protéine de fusion avec 6 histidines, produit par <i>Escherichia coli</i> à partir d'ADN recombinant (non glycosylé) :<br>[427-L-histidine(K>H),428-L-sérine(V>S),429-L-sérine(R>S),430-L-lysine(R>K),431-L-leucine(A>L),432-L-glutamine(R>Q)]proaérolysine d' <i>Aeromonas hydrophila</i> protéine de fusion avec l'hexa-L-histidine   |
| topsalisina  | proaerolisina, proteína formadora de poros, d' <i>Aeromonas hydrophila</i> cuyo sitio furina está substituido por un antígeno prostático específico, proteína de fusión con 6 histidinas, producida por <i>Escherichia coli</i> a partir de ADN recombinante (no glicosilado) :<br>[427-L-histidina(K>H),428-L-serina(V>S),429-L-serina (R>S),430-L-lisina(R>K),431-L-leucina(A>L),432-L-glutamina(R>Q)]proaerolisina d' <i>Aeromonas hydrophila</i> proteína de fusión con hexa-L-histidina  |
| Sequence / Séquence / Secuencia<br>AEFVYFDQLR LFSLGQGVCG DKYRPVNREE AQS VKSNIVG MMGQWQISGL 50<br>ANGWVIMGPG YNGEIKPGTA SNTWCYPTNP VTGEIPTLSA LDIPDGDEVD 100<br>VQWRLVHDSA NFIKPTSyla HYLGYAWVGG NHSQYVGEDM DVTRDGDGWW 150<br>IRGNNDGGCD GYRCGDKTAI KVS NFAYNLD PDSFKHGDTV QSDRQLVKTV 200<br>VGWAVNDSDT PQSGYDVTLR YDTATNWSKT NTYGLSEKVT TKNKFKWPLV 250<br>GETELSLIEIA ANQSWASQNG GSTTSLSLQS VRPTVPARSK IPVKIELYKA 300<br>DISYPYBEKA DVS YDLTSLG FLRWGCNAWY THPDNRPNWN HTEVICPYKD 350<br>KASSIRYQWD KRYIPGEVKW WDNWNTIQQN GLSTMQNNLA RVLRPVPRAGI 400<br>TGDFAESQSF AGNIEIGAPV PLAADSHSSK LQSV DGAQGQ LRLEIPLDAQ 450<br>ELSGLGFNNV SLSVTPAANQ HHHHHH 476 |   |
| Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro<br>19-75 159-164   |   |
| <b>tosatoxumabum #</b><br>tosatoxumab  | immunoglobulin G1-lambda2, anti-[ <i>Staphylococcus aureus</i> alpha-toxin (alpha-hemolysin, alpha-HL, hly, hla)], <i>Homo sapiens</i> monoclonal antibody; gamma1 heavy chain (1-451) [ <i>Homo sapiens</i> VH (IGHV5-51*01 (81.60%) -(IGHD)-IGHJ1*01 L123>M (116)) [8.8.14] (1-121) -IGHG1*01 (CH1 (122-219), hinge (220-234), CH2 (235-344), CH3 (345-449), CHS (450-451)) (122-451)], (224-216')-disulfide with lambda light chain (1'-217') [ <i>Homo sapiens</i> V-LAMBDA (IGLV1-44*01 (93.90%) -IGLJ1*01) [8.3.12] (1'-111') -IGLC1*01 (112'-217')]; dimer (230-230":233-233")-bisdisulfide                    |
| tosatoxumab  | immunoglobuline G1-lambda2, anti-[ <i>Staphylococcus aureus</i> toxine alpha (hémolysine alpha, HL-alpha, hly, hla)], <i>Homo sapiens</i> anticorps monoclonal;<br>chaîne lourde gamma1 (1-451) [ <i>Homo sapiens</i> VH (IGHV5-51*01 (81.60%) -(IGHD)-IGHJ1*01 L123>M (116)) [8.8.14] (1-121) -IGHG1*01 (CH1 (122-219), charnière (220-234), CH2 (235-344), CH3 (345-449), CHS (450-451)) (122-451)], (224-216')-disulfure avec la chaîne légère lambda (1'-217') [ <i>Homo sapiens</i> V-LAMBDA (IGLV1-44*01 (93.90%) -IGLJ1*01) [8.3.12] (1'-111') -IGLC1*01 (112'-217')]; dimère (230-230":233-233")-bisdisulfure |

## tosatouxumab

immunoglobulina G1-lambda2, anti-[toxina alfa de *Staphylococcus aureus* (hemolisina alfa, HL-alfa, hly, hla)], anticuerpo monoclonal de *Homo sapiens*;

gamma1 (1-451) [*Homo sapiens* VH (IGHV5-51\*01 (81.60%) - (IGHD)-IGHJ1\*01 L123>M (116))] [8.8.14] (1-121) -cadena pesada (224-216')-disulfuro con la cadena ligera lambda (1'-217') [*Homo sapiens* (IGLV1-44\*01 (93.90%) -IGLJ1\*01) [8.3.12] (1'-111') - IGLC1\*01 (112'-217')]; dímero (230-230":233-233")-bisdisulfuro

## Heavy chain / Chaîne lourde / Cadena pesada

```
EVQMVQSGAE VKKPGPEPLKI SCKGSGYKFG THWIGWVRQR PGKGLEWMGI 50
IHPADSETKY SPSFQGGQVSF SADKSSNTAY LHWSTLRASD TAMYVCARRS 100
GSSSWYALDF WQGGTMVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV 150
KDYFPEPVTY SWNSGALTSG VHTFPAVLQS SGLYSLSSVY TVPSSSLGTQ 200
TYICNVNHPK SNTKVDKRVK PKSCDKTHTC PPCPAPELLG GPSVFLFPPK 250
PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 350
QVYTLPPSRE EMTKNQVSLT CLVKGFPYPSD IAVEWESNGQ PENNYKTPFP 400
VLDSGDGSFFL YSKLTVDKSR WQGNVFCSS VMHEALHNNY TQKSLSLSPG 450
K 451
```

## Light chain / Chaîne légère / Cadena ligera

```
QSVLTQSPSA SGTPEGQRTI SCSGSSNIG SNTVNWYQQF PGAAPKLLIY 50
TNNQRPQSGVP DRFSGSKSGT SASLAISGLQ SEDEADYYCA TWDDSLNGLY 100
VFGTGTKVTV LGQPKANFTV TLFPPSSEEL QANKATLVCL ISDFYPGAVT 150
VAWKADGSPV KAGVETTKPS KQSNKNYAAS SYLSLTPEQW KSHRSYSCQV 200
THEGSTVEKT VAPTECS 217
```

## Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 148-204 265-325 371-429  
22"-96" 148"-204" 265"-325" 371"-429"

Intra-L (C23-C104) 22"-89" 139"-198"  
22"-89" 139"-198"

Inter-H-L (h 5-CL 126) 224-216' 224"-216"

Inter-H-H (h 11, h 14) 230-230" 233-233"

## N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:  
301, 301"

## tovetumabum #

## tovetumab

immunoglobulin G2-kappa, anti-[*Homo sapiens* PDGFRA (platelet-derived growth factor receptor alpha subunit, PDGFR2, CD140a)], *Homo sapiens* monoclonal antibody;

gamma2 heavy chain (1-446) [*Homo sapiens* VH (IGHV3-11\*01 (98.00%) - (IGHD)-IGHJ6\*01) [8.8.13] (1-120) -IGHG2\*01 (CH1 (121-218), hinge (219-230), CH2 (231-339), CH3 (340-444), CHS (445-446)) (121-446)], (134-215')-disulfide with kappa light chain (1'-215') [*Homo sapiens* V-KAPPA (IGKV1-39\*01 (89.50%) -IGKJ5\*01 I126>M (107)) [6.3.10] (1'-108') -IGKC\*01 (109'-215')]; dimer (222-222":223-223":226-226":229-229")-tetrakisdisulfide

## tovétumab

immunoglobuline G2-kappa, anti-[*Homo sapiens* PDGFRA (sous-unité alpha du récepteur du facteur de croissance dérivé des plaquettes, PDGFR2, CD140a)], *Homo sapiens* anticorps monoclonal;

chaîne lourde gamma2 (1-446) [*Homo sapiens* VH (IGHV3-11\*01 (98.00%) - (IGHD)-IGHJ6\*01) [8.8.13] (1-120) -IGHG2\*01 (CH1 (121-218), charnière (219-230), CH2 (231-339), CH3 (340-444), CHS (445-446)) (121-446)], (134-215')-disulfure avec la chaîne légère kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV1-39\*01 (89.50%) - IGKJ5\*01 I126>M (107)) [6.3.10] (1'-108') -IGKC\*01 (109'-215')]; dimère (222-222":223-223":226-226":229-229")-tétrakisdisulfure

## tovetumab

inmunoglobulina G2-kappa, anti-[PDGFRA de *Homo sapiens* (subunidad alfa del receptor del factor de crecimiento derivado de las plaquetas, PDGFR2, CD140a)], anticuerpo monoclonal de *Homo sapiens*;

cadena pesada gamma2 (1-446) [*Homo sapiens* VH (IGHV3-11\*01 (98.00%) -(IGHD)-IGHJ6\*01) [8.8.13] (1-120) -IGHG2\*01 (CH1 (121-218), bisagra (219-230), CH2 (231-339), CH3 (340-444), CHS (445-446)) (121-446)], (134-215')-disulfuro con la cadena ligera kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV1-39\*01 (89.50%) -IGKJ5\*01 I126>M (107)) [6.3.10] (1'-108') -IGKC\*01 (109'-215')]; dímero (222-222":223-223":226-226":229-229")-tetrakisdisulfuro

## Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVESGSGG LVKPGGSLRL SCAASGFTFS DYYMNWIRQA PGKGLEWVSY 50
ISSSGSIIYY ADSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCAREG 100
RIAARGMDVW GQGTTVTVSS ASTKGPSVFP LAPCSRSTSE STAALGCLVK 150
DYFPEFVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSNFGTQT 200
YTCNVDPKPS NTKVDKTVR KCCVECPPCP APPVAGPSVF LFPKPKDNL 250
MISRTFEVTC VVVDVSHEDP EVQFNWYVDG VEVHNAKTKP REEQFNSTFR 300
VVSVLTVVHQ DNLNGKEYKC KVSNGKLPAP IEKTIKSTKG QPREPQVYTL 350
PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNQGPENNY KTFPPMLDSD 400
GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK 446
```

## Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVS ITCRPSQSFS RYINWYQQKPK GKAPKLLIHA 50
ASSLVGGVPS RFGSGSGSDT FTLTISLQPD EDFATYYCQQ TYSNPPITFG 100
QGTRLEMKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYLSSTL TSKADYKEH KKYACEVTHQ 200
GLSSPVTKSF NRGEK 215
```

## Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22"-96" 147"-203" 260"-320" 366"-424"  
22"-96" 147"-203" 260"-320" 366"-424"

Intra-L (C23-C104) 23"-88" 135"-195"  
23"-88" 135"-195"

Inter-H-L (CH1 10-CL 126) 134"-215" 134"-215"

Inter-H-H (h 4, h 5, h 8, h 11) 222"-222" 223"-223" 226"-226" 229"-229"

## N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:  
296, 296"

## ubrogepantum

## ubrogepant

(3'S)-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl]-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxamide


## ubrogé pant

(3'S)-N-[(3S,5S,6R)-6-méthyl-2-oxo-5-phényl-1-(2,2,2-trifluoroéthyl)pipéridin-3-yl]-2'-oxo-1',2',5,7-tétrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxamide

## ubrogepant

(3'S)-N-[(3S,5S,6R)-6-metil-2-oxo-5-fenil-1-(2,2,2-trifluoroetil)piperidin-3-il]-2'-oxo-1',2',5,7-tetrahidrospiro[ciclopenta[b]piridina-6,3'-pirrolo[2,3-b]piridina]-3-carboxamida

C<sub>29</sub>H<sub>26</sub>F<sub>3</sub>N<sub>5</sub>O<sub>3</sub>



**valbenazinum**


valbenazine

(2*R*,3*R*,11*bR*)-9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11*b*-hexahydro-2*H*-pyrido[2,1-*a*]isoquinolin-2-yl L-valinate

valbénazine

L-valinate de (2*R*,3*R*,11*bR*)-9,10-diméthoxy-3-(2-méthylpropyl)-1,3,4,6,7,11*b*-hexahydro-2*H*-pyrido[2,1-*a*]isoquinoléin-2-yle

valbenazina

L-valinato de (2*R*,3*R*,11*bR*)-9,10-dimetoxi-3-(2-metilpropil)-1,3,4,6,7,11*b*-hexahidro-2*H*-pirido[2,1-*a*]isoquinolein-2-yloC<sub>24</sub>H<sub>38</sub>N<sub>2</sub>O<sub>4</sub>**vantictumabum #**

vantictumab

immunoglobulin G2-lambda, anti-[*Homo sapiens* frizzled family receptor (FZD), including FZD1, FZD2, FZD5, FZD7 and FZD8]], *Homo sapiens* monoclonal antibody;  
 gamma2 heavy chain (1-443) [*Homo sapiens* VH (IGHV3-23\*04 (90.80%) -(IGHD)-IGHJ6\*01 T123>L (113)) [8.8.11] (1-118) -IGHG2\*01 (CH1 (119-216), hinge (217-228), CH2 (229-337), CH3 (338-441), CHS (442-443)) (119-443)], (132-212')-disulfide with lambda light chain (1'-213') [*Homo sapiens* V-LAMBDA (IGLV3-25\*02 (81.60%) -IGLJ2\*01 [6.3.10] (1'-107') -IGLC2\*01 (108'-213'))]; dimer (220-220":221-221":224-224":227-227")-tetrakisdisulfide

vantictumab

immunoglobuline G2-lambda, anti-[*Homo sapiens* récepteur de la famille frizzled (FZD), incluant FZD1, FZD2, FZD5, FZD7 et FZD8]], *Homo sapiens* anticorps monoclonal;  
 chaîne lourde gamma2 (1-443) [*Homo sapiens* VH (IGHV3-23\*04 (90.80%) -(IGHD)-IGHJ6\*01 T123>L (113)) [8.8.11] (1-118) -IGHG2\*01 (CH1 (119-216), charnière (217-228), CH2 (229-337), CH3 (338-441), CHS (442-443)) (119-443)], (132-212')-disulfure avec la chaîne légère lambda (1'-213') [*Homo sapiens* V-LAMBDA (IGLV3-25\*02 (81.60%) -IGLJ2\*01 [6.3.10] (1'-107') -IGLC2\*01 (108'-213'))]; dimère (220-220":221-221":224-224":227-227")-tétrakisdisulfure

vantictumab

inmunoglobulina G2-lambda, anti-[receptor de la familia frizzled (FZD) de *Homo sapiens*, incluyendo FZD1, FZD2, FZD5, FZD7 et FZD8]], anticuerpo monoclonal de *Homo sapiens* ;  
 cadena pesada gamma2 (1-443) [*Homo sapiens* VH (IGHV3-23\*04 (90.80%) -(IGHD)-IGHJ6\*01 T123>L (113)) [8.8.11] (1-118) -IGHG2\*01 (CH1 (119-216), bisagra (217-228), CH2 (229-337), CH3 (338-441), CHS (442-443)) (119-443)], (132-212')-disulfuro con la cadena ligera lambda (1'-213') [*Homo sapiens* V-LAMBDA (IGLV3-25\*02 (81.60%) -IGLJ2\*01 [6.3.10] (1'-107') -IGLC2\*01 (108'-213'))]; dímero (220-220":221-221":224-224":227-227")-tetraakisdisulfuro

## Heavy chain / Chaîne lourde / Cadena pesada

|            |            |            |            |            |     |
|------------|------------|------------|------------|------------|-----|
| EVQLVESGGG | LVQPGGSLRL | SCAASGFTFS | HYTLSWVRQA | PGKGLEWVSV | 50  |
| ISGDGSYTY  | ADSVKGRFTI | SSDNSKNTLY | LQMNSLRAED | TAVYYCARNF | 100 |
| IKYVFANWQ  | GTLTVSSAS  | TKGPSVFPLA | PCSRSTSEST | AALGCLVKDY | 150 |
| FPEPVTWSN  | SGALTSGVHT | FPAVLQSSGL | YSLSSVVTVP | SSNFGTQTYT | 200 |
| CNVDHKPSNT | KVDKTVERRK | CVECPPCPAP | FVAGPSVFLF | PPKPKDTLMI | 250 |
| SRTPEVTCVV | VDVSHEDPEV | QFNWYVDGVE | VHNAKTKPRE | EQFNSTFRVV | 300 |
| SVLTVVHQDW | LNGKEYKCKV | SNKGLPAPIE | KTISKTKGQP | REPQVYTLFP | 350 |
| SREEMTKNQV | SLTCLVKGFY | PSDIAVEWES | NGQPENNYKT | TPFMLDSDGS | 400 |
| FFLYSKLTVD | KSRWQQGNVF | SCSVMEALH  | NHYTEKSLSL | SPG        | 443 |

## Light chain / Chaîne légère / Cadena ligera

|            |            |            |             |            |     |
|------------|------------|------------|-------------|------------|-----|
| DIELTQPPSV | SVAPGQTARI | SCSGDNIGSF | YVHWYQQKPG  | QAPFLVIYDK | 50  |
| SNRPSGIPER | FSGSNSGNTA | TLTISGTQAE | DEADYTCQSY  | ANTLSLVFGG | 100 |
| GTKLTVLGQP | KAAPSVTLFP | PSSEELQANK | ATLVCLISDF  | YPGAVTVAWK | 150 |
| ADSSPVKAGV | ETTPSKQSN  | NKYAASSYLS | LTPEQWQKSHR | SYSCQVTHEG | 200 |
| STVEKTVAPT | ECS        |            |             |            | 213 |

## Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

|                    |         |           |           |           |
|--------------------|---------|-----------|-----------|-----------|
| Intra-H (C23-C104) | 22-96   | 145-201   | 258-318   | 364-422   |
|                    | 22"-96" | 145"-201" | 258"-318" | 364"-422" |

|                    |             |               |
|--------------------|-------------|---------------|
| Intra-L (C23-C104) | 22"-87"     | 135"-194"     |
|                    | 22'''-87''' | 135'''-194''' |

|                           |          |             |
|---------------------------|----------|-------------|
| Inter-H-L (CH1 10-CL 126) | 132-212' | 132"-212''' |
|---------------------------|----------|-------------|

|                                 |          |          |          |          |
|---------------------------------|----------|----------|----------|----------|
| Inter-H-H (h 4, h 5, h 8, h 11) | 220-220" | 221-221" | 224-224" | 227-227" |
|---------------------------------|----------|----------|----------|----------|

## N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:  
294, 294"

**vatiquinonum**

vatiquinone


2-[(3*R*,6*E*,10*E*)-3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10,14-trien-1-yl]-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione

vatiquinone

2-[(3*R*,6*E*,10*E*)-3-hydroxy-3,7,11,15-tétraméthylhexadéca-6,10,14-trién-1-yl]-3,5,6-triméthylcyclohexa-2,5-diène-1,4-dione

vatiquinona

2-[(3*R*,6*E*,10*E*)-3-hidroxi-3,7,11,15-tetrametilhexadeca-6,10,14-trien-1-il]-3,5,6-trimetilciclohexa-2,5-dieno-1,4-diona

C<sub>29</sub>H<sub>44</sub>O<sub>3</sub>**vedroprevirum**

vedroprevir


1-[[[(2*S*,4*R*)-1-[(2*S*)-2-[[[(1*R*,3*r*,5*S*)-bicyclo[3.1.0]hexan-3-yl]oxy]carbonyl]amino]-3,3-dimethylbutanoyl]-4-[(8-chloro-7-[2-(morpholin-4-yl)ethoxy]-2-{2-[(propan-2-yl)amino]-1,3-thiazol-4-yl]quinolin-4-yl)oxy]pyrrolidin-2-yl]carbonylamino]-2-ethylcyclopropane-1-carboxylic acid

védroprévír

acide 1-[[[(2*S*,4*R*)-1-[(2*S*)-2-[[[(1*R*,3*r*,5*S*)-bicyclo[3.1.0]hexan-3-yl]oxy]carbonyl]amino]-3,3-diméthylbutanoyl]-4-[(8-chloro-7-[2-(morpholin-4-yl)éthoxy]-2-{2-[(propan-2-yl)amino]-1,3-thiazol-4-yl]quinoléin-4-yl)oxy]pyrrolidin-2-yl]carbonylamino]-2-éthylcyclopropane-1-carboxylique

vedroprevir

ácido 1-[[[(2*S*,4*R*)-1-[(2*S*)-2-[[[(1*R*,3*r*,5*S*)-biciclo[3.1.0]hexan-3-il]oxi]carbonil]amino]-3,3-dimetilbutanoil]-4-[(8-cloro-7-[2-(morfolin-4-il)etoxi]-2-{2-[(propan-2-il)amino]-1,3-tiazol-4-il]quinolin-4-il]oxi]pirrolidin-2-il]carbonilamino]-2-etilciclopropano-1-carboxílico

C<sub>45</sub>H<sub>60</sub>ClN<sub>7</sub>O<sub>9</sub>S

**vericiguatum**  
vericiguat


methyl [4,6-diamino-2-{5-fluoro-1-[(2-fluorophenyl)methyl]-1*H*-pyrazolo[3,4-*b*]pyridin-3-yl}pyrimidin-5-yl]carbamate

vériciguat

[4,6-diamino-2-{5-fluoro-1-[(2-fluorophényl)méthyl]-1*H*-pyrazolo[3,4-*b*]pyridin-3-yl}pyrimidin-5-yl]carbamate de méthyle

vericiguat

*N*-[4,6-diamino-2-{5-fluoro-1-[(2-fluorofenil)metil]-1*H*-pirazolo[3,4-*b*]piridin-3-il]pirimidin-5-il]carbamato de metilo

C<sub>19</sub>H<sub>16</sub>F<sub>2</sub>N<sub>6</sub>O<sub>2</sub>

**vilaprisanum**  
vilaprisan


20,20,21,21,21-pentafluoro-17-hydroxy-11β-[4-(methanesulfonyl)phenyl]-19-nor-17α-pregna-4,9-dien-3-one

vilaprisan

20,20,21,21,21-pentafluoro-17-hydroxy-11β-[4-(méthanesulfonyl)phényl]-19-nor-17α-prégna-4,9-dién-3-one

vilaprisán

20,20,21,21,21-pentafluoro-17-hidroxi-11β-[4-(metanosulfonyl)fenil]-19-nor-17α-pregna-4,9-dien-3-ona

C<sub>27</sub>H<sub>29</sub>F<sub>5</sub>O<sub>4</sub>S

**voruciclibum**


voruciclib

2-[2-chloro-4-(trifluoromethyl)phenyl]-5,7-dihydroxy-8-[(2*R*,3*S*)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]-4*H*-1-benzopyran-4-one

voruciclib

2-[2-chloro-4-(trifluoromethyl)phenyl]-5,7-dihydroxy-8-[(2*R*,3*S*)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]-4*H*-1-benzopyran-4-one

voruciclib

2-[2-cloro-4-(trifluorometil)fenil]-5,7-dihidroxi-8-[(2*R*,3*S*)-2-(hidroximetil)-1-metilpirrolidin-3-il]-4*H*-1-benzopiran-4-onaC<sub>22</sub>H<sub>19</sub>ClF<sub>3</sub>NO<sub>5</sub># Electronic structure available on Mednet: <http://mednet.who.int/># Structure électronique disponible sur Mednet: <http://mednet.who.int/># Estructura electrónica disponible en Mednet: <http://mednet.who.int/>\* [http://www.who.int/entity/medicines/services/inn/Radical\\_Book\\_2012.pdf](http://www.who.int/entity/medicines/services/inn/Radical_Book_2012.pdf)

**AMENDMENTS TO PREVIOUS LISTS  
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES  
MODIFICACIONES A LAS LISTAS ANTERIORES**

**Recommended International Nonproprietary Names (Rec. INN): List 1  
(Chron. Wld Hlth Org., Vol. 9, No 6, 1955)**

|        |  |   |
|--------|--|---|
| p. 190 | <i>delete</i><br><b>methacholinii chloridum</b><br>methacholinium chloride | <i>insert</i><br><b>methacholini chloridum</b><br>methacholine chloride |
|--------|--|---|

**Dénominations communes internationales recommandées (DCI rec.): Liste 1  
(Chron. Org. mond. Santé, Vol. 9, No 6, 1955)**

|        |  |   |
|--------|--|---|
| p. 206 | <i>supprimer</i><br><b>methacholinii chloridum</b><br>chlorure de méthacholinium | <i>insérer</i><br><b>methacholini chloridum</b><br>chlorure de méthacholine |
|--------|--|---|

**Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 1  
(Crón. Org. mund. Salud, Vol. 9, No 6, 1955)**

|        |  |  |
|--------|--|--|
| p. 209 | <i>suprimáse</i><br><b>methacholinii chloridum</b><br>cloruro de metacolinio | <i>insertese</i><br><b>methacholini chloridum</b><br>cloruro de metacolina |
|--------|--|--|

**Recommended International Nonproprietary Names (Rec. INN): List 3  
(Chron. Wld Hlth Org., Vol. 13, No. 12, 1959)**

|        |  |   |
|--------|--|---|
| p. 463 | <i>delete</i><br><b>acetylcholinii chloridum</b>                               | <i>insert</i><br><b>acetylcholini chloridum</b>                             |
| p. 465 | <i>delete</i><br><b>cholinii chloridum</b>                                     | <i>insert</i><br><b>cholini chloridum</b>                                   |
| p. 470 | <i>delete</i><br><b>nitricholinii perchloras</b><br>nitricholinium perchlorate | <i>insert</i><br><b>nitricholini perchloras</b><br>nitricholine perchlorate |

**Dénominations communes internationales recommandées (DCI rec.): Liste 3  
(Chron. Org. mond. Santé, Vol. 13, No. 12, 1959)**

|        |   |  |
|--------|---|--|
| p. 482 | <i>supprimer</i><br><b>acetylcholinii chloridum</b> | <i>insérer</i><br><b>acetylcholini chloridum</b> |
|--------|---|--|



---

|        |  |   |
|--------|--|---|
| p. 484 | <i>supprimer</i><br><b>cholinii chloridum</b>  | <i>insérer</i><br><b>cholini chloridum</b>                                      |
| p. 489 | <i>supprimer</i><br><b>nitricholinii perchloras</b><br>perchlorate de nitricholinium | <i>insérer</i><br><b>nitricholini perchloras</b><br>perchlorate de nitricholine |

**Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 3**  
(*Crón. Org. mund. Salud, Vol. 13, No. 12, 1959*)

|        |   |   |
|--------|---|---|
| p. 496 | <i>suprimáse</i><br><b>acetylcholinii chloridum</b>                               | <i>insertese</i><br><b>acetylcholini chloridum</b>                              |
| p. 498 | <i>suprimáse</i><br><b>cholinii chloridum</b>                                     | <i>insertese</i><br><b>cholini chloridum</b>                                    |
| p. 503 | <i>suprimáse</i><br><b>nitricholinii perchloras</b><br>perclorato de nitricolinio | <i>insertese</i><br><b>nitricholini perchloras</b><br>perclorato de nitrocolina |

**Recommended International Nonproprietary Names (Rec. INN): List 4**  
(*Chron. Wld Hlth Org., Vol. 16, No. 3, 1962*)

|        |  |   |
|--------|--|---|
| p. 103 | <i>delete</i><br><b>cholinii gluconas</b><br>cholinium gluconate | <i>insert</i><br><b>cholini gluconas</b><br>choline gluconate |
|--------|--|---|

**Dénominations communes internationales recommandées (DCI rec.): Liste 4**  
(*Chron. Org. mond. Santé, Vol. 16, No. 3, 1962*)

|        |  |   |
|--------|--|---|
| p. 114 | <i>supprimer</i><br><b>cholinii gluconas</b><br>gluconate de cholinium | <i>insérer</i><br><b>cholini gluconas</b><br>gluconate de choline |
|--------|--|---|

**Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 4**  
(*Crón. Org. mund. Salud, Vol. 16, No. 3, 1962*)

|        |  |  |
|--------|--|--|
| p. 154 | <i>suprimáse</i><br><b>cholinii gluconas</b><br>gluconato de colinio | <i>insertese</i><br><b>cholini gluconas</b><br>gluconato de colina |
|--------|--|--|

**Recommended International Nonproprietary Names (Rec. INN): List 62**  
**Dénominations communes internationales recommandées (DCI Rec.): Liste 62**  
**Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 62**  
**(WHO Drug Information, Vol. 23, No. 3, 2009)**

|                 |   |  |
|-----------------|---|--|
| p. 258 &<br>259 | <b>ramucirumabum #</b><br>ramucirumab<br>ramucirumab<br>ramucirumab | <i>replace the description and the structure by the following ones</i><br><i>remplacer la description et la structure par les suivantes</i><br><i>sustitúyase la descripción y la estructura por los siguientes</i>  |
|                 |   | immunoglobulin G1-kappa, anti-[ <i>Homo sapiens</i> KDR (kinase insert domain receptor, vascular endothelial growth factor receptor 2, VEGFR2, VEGF-R2, FLK1, CD309) extracellular domain], <i>Homo sapiens</i> monoclonal antibody;<br>gamma1 heavy chain (1-446) [ <i>Homo sapiens</i> VH (IGHV3-21*01 (99.00%) - (IGHD)-IGHJ3*02) [8.8.9] (1-116) - IGHG1*03 (CH1 F5>L (125), hinge (215-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-214')-disulfide with kappa light chain (1'-214') [ <i>Homo sapiens</i> V-KAPPA (IGKV1-12*01 (85.30%) -IGKJ4*01 E125>D (105)) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimer (225-225'':228-228'')-bisdisulfide                                   |
|                 |   | immunoglobuline G1-kappa, anti-[ <i>Homo sapiens</i> KDR (récepteur à domaine insert kinase, récepteur 2 du facteur de croissance endothélial vasculaire, VEGFR2, VEGF-R2, FLK1, CD309) domaine extracellulaire], <i>Homo sapiens</i> anticorps monoclonal;<br>chaîne lourde gamma1 (1-446) [ <i>Homo sapiens</i> VH (IGHV3-21*01 (99.00%) - (IGHD)-IGHJ3*02) [8.8.9] (1-116) -IGHG1*03 (CH1 F5>L (125), charnière (215-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-214')-disulfure avec la chaîne légère kappa (1'-214') [ <i>Homo sapiens</i> V-KAPPA (IGKV1-12*01 (85.30%) -IGKJ4*01 E125>D (105)) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (225-225'':228-228'')-bisdisulfure |
|                 |   | inmunoglobulina G1-kappa, anti-[ <i>Homo sapiens</i> KDR (receptor con dominio insert-kinasa, receptor 2 del factor de crecimiento endotelial vascular, VEGFR2, VEGF-R2, FLK1, CD309) dominio extracelular], <i>Homo sapiens</i> anticuerpo monoclonal;<br>cadena pesada gamma1 (1-446) [ <i>Homo sapiens</i> VH (IGHV3-21*01 (99.00%) - (IGHD)-IGHJ3*02) [8.8.9] (1-116) -IGHG1*03 (CH1 F5>L (125), bisagra (215-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-214')-disulfuro con la cadena ligera kappa (1'-214') [ <i>Homo sapiens</i> V-KAPPA (IGKV1-12*01 (85.30%) -IGKJ4*01 E125>D (105)) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (225-225'':228-228'')-bisdisulfuro        |

**Error! Objects cannot be created from editing field codes.**

**Recommended International Nonproprietary Names (Rec. INN): List 67**  
**Dénominations communes internationales recommandées (DCI Rec.): Liste 67**  
**Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 67**  
**(WHO Drug Information, Vol. 26, No. 1, 2012)**

|       |   |   |
|-------|---|---|
| p. 91 | <b>upamostatum</b><br>upamostat<br>upamostat<br>upamostat | <i>replace the chemical name by the following one</i><br><i>remplacer le nom chimique par le suivant</i><br><i>sustitúyase el nombre químico por el siguiente</i> |
|       |   | ethyl 4-((2S)-3-{3-[(E)-N'-hydroxycarbamimidoyl]phenyl}-2-[2,4,6-tri(propan-2-yl)benzenesulfonamido]propanoyl)piperazine-1-carboxylate}                           |
|       |   | 4-((2S)-3-{3-[(E)-N'-hydroxycarbamimidoyl]phényl}-2-[2,4,6-tri(propan-2-yl)benzènesulfonamido]propanoyl)pipérazine-1-carboxylate d'éthyle                         |
|       |   | 4-((2S)-3-{3-[(E)-N'-hidroxycarbamimidoyl]fenil}-2-[2,4,6-tri(propan-2-il)bencenosulfonamido]propanoil)piperazina-1-carboxilato de etilo                          |

**Recommended International Nonproprietary Names (Rec. INN): List 69**

**Dénominations communes internationales recommandées (DCI Rec.): Liste 69****Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 69****(WHO Drug Information, Vol. 27, No. 1, 2013)**

|       |                    |   |
|-------|--------------------|---|
| p. 82 | <b>tenapanorum</b> |   |
|       | tenapanor          | <i>replace the chemical name by the following one</i>   |
|       | ténapanor          | <i>remplacer le nom chimique par le suivant</i>   |
|       | tenapanor          | <i>sustitúyase el nombre químico por el siguiente</i>   |
|       |                    | <i>N,N'-(10,17-dioxo-3,6,21,24-tetraoxa-9,11,16,18-tetraazahexacosane-1,26-diyl)bis[3-[(4S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl]benzenesulfonamide}</i>  |
|       |                    | <i>N,N'-(10,17-dioxo-3,6,21,24-tetraoxa-9,11,16,18-tetraazahexacosane-1,26-diyl)bis[3-[(4S)-6,8-dichloro-2-méthyl-1,2,3,4-tétrahydroisoquinoléin-4-yl]benzènesulfonamide}</i> |
|       |                    | <i>N,N'-(10,17-dioxo-3,6,21,24-tetraoxa-9,11,16,18-tetraazahexacosano-1,26-diyl)bis[3-[(4S)-6,8-dicloro-2-metil-1,2,3,4-tetrahidroisoquinolin-4-il]bencenosulfonamida}</i>    |


**Recommended International Nonproprietary Names (Rec. INN): List 70****Dénominations communes internationales recommandées (DCI Rec.): Liste 70****Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 70****(WHO Drug Information, Vol. 27, No. 3, 2013)**

|                 |                                  |   |
|-----------------|----------------------------------|---|
| p. 306<br>& 307 | <b>polatuzumabum vedotinum #</b> |   |
|                 | polatuzumab vedotin              | <i>replace the description by the following one</i>   |
|                 | polatuzumab védotine             | <i>remplacer la description par la suivante</i>   |
|                 | polatuzumab vedotina             | <i>sustitúyase la descripción por la siguiente</i>  |
|                 |                                  | immunoglobulin G1-kappa auristatin E conjugate, anti-[ <i>Homo sapiens</i> CD79B (immunoglobulin-associated CD79 beta)], humanized monoclonal antibody conjugated to auristatin E;<br>gamma1 heavy chain (1-447) [humanized VH ( <i>Homo sapiens</i> IGHV3-23*04 (76.50%) - (IGHD)-IGHJ4*01) [8.8.10] (1-117) - <i>Homo sapiens</i> IGHG1*03 (CH1 R120>K (214) (118-215), hinge (216-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-218')-disulfide with kappa light chain (1'-218') [humanized V-KAPPA ( <i>Homo sapiens</i> IGKV1-39*01 (85.90%) -IGKJ1*01) [10.3.9] (1'-111') - <i>Homo sapiens</i> IGKC*01 (112'-218')]; dimer (226-226":229-229")-bisdisulfide; conjugated, on an average of 3 to 4 cysteinyl, to monomethylauristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinyl- <i>p</i> -aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker<br>For the vedotin part, please refer to the document "INN for pharmaceutical substances: Names for radicals, groups and others"                          |
|                 |                                  | immunoglobuline G1-kappa conjuguée à l'auristatine E, anti-[ <i>Homo sapiens</i> CD79B (CD79 bêta associé à l'immunoglobuline)], anticorps monoclonal humanisé conjugué à l'auristatine E;<br>chaîne lourde gamma1 (1-447) [VH humanisé ( <i>Homo sapiens</i> IGHV3-23*04 (76.50%) - (IGHD)-IGHJ4*01) [8.8.10] (1-117) - <i>Homo sapiens</i> IGHG1*03 (CH1 R120>K (214) (118-215), charnière (216-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-218')-disulfure avec la chaîne légère kappa (1'-218') [V-KAPPA humanisé ( <i>Homo sapiens</i> IGKV1-39*01 (85.90%) -IGKJ1*01) [10.3.9] (1'-111') - <i>Homo sapiens</i> IGKC*01 (112'-218')]; dimère (226-226":229-229")-bisdisulfure; conjugué, sur 3 à 4 cystéinyl en moyenne, au monométhylauristatine E (MMAE), via un linker clivable de type maléimidocaproyl-valyl-citrullinyl- <i>p</i> -aminobenzyloxycarbonyl (mc-val-cit-PABC)<br>Pour la partie védotine, veuillez vous référer au document "INN for pharmaceutical substances: Names for radicals, groups and others" |
|                 |                                  | immunoglobulina G1-kappa conjugada con auristatina E, anti-[ <i>Homo sapiens</i> CD79B (CD79 beta asociado a la inmunoglobulina)], anticuerpo monoclonal humanizado conjugado con auristatina E;<br>cadena pesada gamma1 (1-447) [VH humanizado ( <i>Homo sapiens</i> IGHV3-23*04 (76.50%) - (IGHD)-IGHJ4*01) [8.8.10] (1-117) - <i>Homo sapiens</i> IGHG1*03 (CH1 R120>K (214) (118-215), bisagra (216-230), CH2 (231-340), CH3 (341-445), CHS   |

(446-447)) (118-447)], (220-218')-disulfuro con la cadena ligera kappa (1'-218') [V-KAPPA humanizado (*Homo sapiens* IGKV1-39\*01 (85.90%) -IGKJ1\*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC\*01 (112'-218')]; dímero (226-226":229-229")-bisdisulfuro; conjugado, en 3 a 4 restos cisteinil por término medio, con monometilauristatina E (MMAE), mediante un vínculo escindible maleimidocaproil-valil-citrullinil-*p*-aminobenziloxycarbonil (mc-val-cit-PABC)  
Para la fracción *vedotina* se pueden referir al documento "*INN for pharmaceutical substances: Names for radicals, groups and others*".

p. 313      **sofosbuvirum**  
sofosbuvir  
sofosbuvir  
sofosbuvir

replace the structure by the following one  
remplacer la structure par la suivante  
sustitúyase la estructura por la siguiente



#### Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.